HK40040495A

HK40040495A - Pyrazole derivatives as malt1 inhibitors

Info

Publication number: HK40040495A
Application number: HK62021030934.5A
Authority: HK
Inventors: Tianbao Lu; Peter J. Connolly; Maxwell David Cummings; Gaston Stanislas Marcella Diels; Jan Willem Thuring; Ulrike Philippar; James Patrick EDWARDS; Didier Jean-Claude Berthelot; Tongfei Wu
Original assignee: Janssen Pharmaceutica Nv
Priority date: 2018-06-18
Filing date: 2019-06-13
Publication date: 2021-07-30

Description

Pyrazole derivatives as MALT1 inhibitors

Cross Reference to Related Applications

This patent application claims priority to us patent application 62/686,451 filed on 18/6/2018, which is incorporated herein by reference.

Technical Field

The present invention relates to novel compounds which are inhibitors of MALT1 (mucosal associated lymphoid tissue lymphoma translocator 1). These compounds are useful for treating diseases, syndromes, conditions or disorders, particularly MALT 1-related diseases, syndromes, conditions or disorders, including but not limited to cancer and immune diseases. The invention also relates to pharmaceutical compositions comprising one or more such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for treating cancer and autoimmune diseases, syndromes, disorders, or conditions associated with inhibitors of MALT 1.

Background

MALT1 (mucosal associated lymphoid tissue lymphoma translocation egg)White 1) is classical NF_KB key medium of the signal conduction pathway. MALT1 is the only human caspase and transduces signals from the B Cell Receptor (BCR) and the T Cell Receptor (TCR). MALT1 is the active subunit of the CBM complex, which forms upon receptor activation. CBM complexes are composed of multiple subunits of three proteins: CARD11 (caspase recruitment domain family member 11), BCL10 (B-cell CLL/lymphoma 10), and MALT 1. MALT1 affects NF through two mechanisms_KB, signal conduction: first, MALT1 functions as a scaffold protein and recruits NF_KB signal proteins such as TRAF6, TAB-TAK1 or NEMO-IKK α/β; second, MALT1 cleavage as a cysteine protease and thus deactivation of NF_KA negative regulator of B signaling, such as RelB, a20, or CYLD. The final endpoint for MALT1 activity was NF_KNuclear translocation of B transcription factor complexes and NF_KActivation of B signaling (Jaworski et al, Cell Mol Life Science, 2016, vol. 73, pp. 459-473).

NF_KConstitutive activation of B signaling is a hallmark of ABC-DLBCL (diffuse large B-cell lymphoma of an activated B-cell-like subtype), a more aggressive form of DLBCL. DLBCL is the most common form of non-hodgkin lymphoma (NHL), accounting for about 25% of lymphoma cases, while ABC-DLBCL accounts for about 40% of DLBCL. NF_KB pathway activation is driven by mutations in signaling components such as CD79A/B, CARD11, MYD88 or A20 in ABC-DLBCL patients (Staudt, Cold Spring Harb Perspectrum Biol 2010, Vol 2; Lim et al, Immunol Rev 2012, Vol 246, p 359-.

The use of BTK inhibitors (e.g., ibrutinib) provides clinical proof-of-concept, i.e., inhibition of NF in ABC-DLBCL_KB signaling is effective. MALT1 is NF_KDownstream of BTK in the B signaling pathway, and MALT1 inhibitors can target ABC-DLBCL patients who do not respond to ibrutinib, mainly patients with CARD11 mutations, as well as patients who acquire resistance to ibrutinib.

Small molecule tool compound inhibitors of MALT1 protease have proven effective in preclinical models of ABC-DLBCL (Fontan et al, Cancer Cell, 2012, Vol.22, p. 812-824; Nagel et al, Cancer Cell, 2012, Vol.22, p. 825-837). Interestingly, covalent catalytic sites and allosteric inhibitors of MALT1 protease function have been described, suggesting that inhibitors of this protease may be useful as agents (Demeyer et al Trends Mol Med, 2016, Vol.22, p.135-150).

Chromosomal translocations that produce the API2-MALT1 fusion oncoprotein are the most common mutations identified in MALT (mucosa-associated lymphoid tissue) lymphomas. API2-MALT1 is NF_KPotent activators of the B pathway (Rosebeck et al, World J Biol Chem, 2016, Vol 7, p. 128-137). API2-MALT1 mimics ligand-bound TNF receptors and promotes TRAF 2-dependent ubiquitination of RIP1, which serves to activate classical NF_KB signaling scaffold. In addition, API2-MALT1 has been shown to cleave and produce NF_KB induces stable, constitutively active fragments of kinases (NIKs) to activate atypical NF_KB channel (Rosebeck et al, Science 2011, vol 331, p.468-472).

In addition to lymphomas, MALT1 has been shown to play a key role in innate and adaptive immunity (Jaworski M et al, Cell Mol Life sci., 2016). MALT1 protease inhibitors can reduce the disease onset and progression of experimental allergic encephalomyelitis (a mouse model of multiple sclerosis) in mice (Mc Guire et al, j. neuroin flumation, 2014, vol 11, p 124). Mice expressing catalytically inactive MALT1 mutants exhibited loss of marginal zone B cells and B1B cells, as well as general immunodeficiency characterized by reduced T and B cell activation and proliferation. However, these mice also develop spontaneous multi-organ autoimmune inflammation at 9 to 10 weeks of age. It is still difficult to understand why knockout mice of MALT1 protease death show a disruption in tolerance, whereas conventional MALT1 KO mice do not. One hypothesis suggests that immune homeostasis imbalance in knockout mice with MALT1 protease death may be due to incomplete deficiency of T and B cells, but severe deficiency of immunoregulatory cells (Jaworski et al, EMBO j., 2014; gewires et al, Cell Reports, 2014; born ancin et al, j. immunology, 2015; Yu et al, PLOS One, 2015). Similarly, MALT deficiency in humans has been associated with generalized immunodeficiency (McKinnon et al, J.allergy Clin.Immunol.2014,133, 1458-1462; Jabara et al, J.allergy Clin.Immunol.2013,132, 151-158; Punwani et al, J.Clin.Immunol.2015,35, 135-. Given the differences between gene mutations and pharmacological inhibition, the phenotype of the knockout mice for MALT1 protease death may not be similar to that of patients treated with MALT1 protease inhibitors. Reduction of immunosuppressive T cells by inhibition of MALT1 protease may be beneficial to cancer patients by potentially increasing anti-tumor immunity.

Thus, inhibitors of MALT1 of the present invention may provide therapeutic benefits to patients suffering from cancer and/or immune diseases.

Disclosure of Invention

The invention relates to compounds of formula (I)

Wherein

R₁Is independently selected from pyrazolo [1,5-a ]]Pyridyl and imidazo [1,2-a ]]Heteroaryl of pyridyl; wherein R is₁Optionally substituted independently with one or two substituents selected from methyl, ethyl, fluoro, chloro, cyano or aminocarbonyl;

R₂independently selected from C_1-4Alkyl, 1-methoxyethyl, difluoromethyl, fluoro, chloro, bromo, cyano, methylsulfonyl, and trifluoromethyl;

G₁is N or C (R)₄)；

G₂Is N or C (R)₃) (ii) a So that in any case G₁And G₂Only one of them is N;

R₃independently selected from trifluoromethyl, cyano, C_1-4Alkyl, fluoro, chloro, bromo, methylcarbonyl, methylthio, methylsulfinyl and methylsulfonyl;

R₄independently selected from triazolyl, 1- (methoxy) ethyl, oxazolyl, isoxazolyl, pyrazolyl, pyrrolyl, thiazoOxazolyl, tetrazolyl, oxadiazolyl, and imidazolyl; wherein R is other than 1-methoxyethyl₄Optionally independently selected from oxo, C_1-4Alkyl, carboxyl, methoxycarbonyl, aminocarbonyl, hydroxymethyl, aminomethyl, (dimethylamino) methyl, amino, methoxymethyl, trifluoromethyl, amino (C)_2-4Alkyl) amino or cyano substituted with one or two substituents; or R₄Independently selected from tetrahydrofuran-2-yl, CH₃SO₂-、(CH₃)₂S (═ O) (═ N) — and CH₃(NH＝)(O＝)S-；

R₅Independently selected from hydrogen, methyl, ethyl, fluoro, chloro, bromo, trifluoromethyl, methylthio, methylsulfonyl, methoxy and cyano;

R₆is hydrogen, C_1-4Alkyl, fluoro, 2-methoxyethoxy, chloro, cyano or trifluoromethyl;

R₇is hydrogen, methyl, ethyl or fluorine;

or an enantiomer, diastereomer, or pharmaceutically acceptable salt form thereof.

The present invention also provides a pharmaceutical composition comprising, consisting of and/or consisting essentially of: a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient and/or a pharmaceutically acceptable diluent, and a compound of formula (I) or a pharmaceutically acceptable salt form thereof.

The present invention also provides a process for preparing a pharmaceutical composition comprising, consisting of and/or consisting essentially of the steps of: mixing a compound of formula (I) with a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient and/or a pharmaceutically acceptable diluent.

The present invention also provides methods of using compounds of formula (I) to treat or ameliorate a disease, syndrome, condition or disorder in a subject, including mammals and/or humans in which the disease, syndrome or condition (including but not limited to cancer and/or immune diseases) is affected by inhibition of MALT 1.

The invention also relates to the use of any of the compounds described herein in the manufacture of a medicament for the treatment of a disease, syndrome, condition or disorder affected by the inhibition of MALT1, such as cancer and/or an immunological disease.

The invention also relates to the preparation of substituted pyrazole derivatives which are useful as inhibitors of MALT 1.

For example, the invention is a method of treating a disease, syndrome, condition or disorder mediated by MALT1, selected from the group consisting of lymphoma, leukemia, cancer and a malignant neoplasm, such as non-hodgkin's lymphoma (NHL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, hodgkin's lymphoma, burkitt's lymphoma, multiple myeloma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), fahrenheit macroglobulinemia, lymphocytic T-cell leukemia, Chronic Myelogenous Leukemia (CML), hairy cell leukemia, acute lymphocytic T-cell leukemia, plasmacytoma, immunoblastic large cell leukemia, lymphoma, leukemia, Megakaryocytic leukemia, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, brain (glioma), glioblastoma, breast cancer, colorectal/colon cancer, prostate cancer, lung cancer (including non-small cell lung cancer), gastric cancer, endometrial cancer, melanoma, pancreatic cancer, liver cancer, kidney cancer, squamous cell carcinoma, ovarian cancer, sarcoma, osteosarcoma, thyroid cancer, bladder cancer, head and neck cancer, testicular cancer, ewing's sarcoma, rhabdomyosarcoma, medulloblastoma, neuroblastoma, cervical cancer, kidney cancer, urothelial cancer, vulval cancer, esophageal cancer, salivary gland carcinoma, nasopharyngeal cancer, buccal cancer, oral cancer, and GIST (gastrointestinal stromal tumor), the method comprises administering to a subject in need thereof a therapeutically effective amount of any of the compounds or pharmaceutical compositions described herein, consisting of and/or consisting essentially of the foregoing.

In another embodiment, the invention relates to a compound of formula (I) for use in treating a disease, syndrome, condition or disorder affected by inhibition of MALT1, selected from lymphoma, leukemia, cancer and malignancies, such as non-hodgkin's lymphoma (NHL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, hodgkin's lymphoma, burkitt's lymphoma, multiple myeloma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), fahrenheit macroglobulinemia, lymphocytic T-cell leukemia, Chronic Myelogenous Leukemia (CML), hairy cell leukemia, acute lymphocytic T-cell leukemia, Plasmacytoma, immunoblastic large cell leukemia, megakaryocytic leukemia, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, brain (glioma), glioblastoma, breast cancer, colorectal/colon cancer, prostate cancer, lung cancer (including non-small cell lung cancer), gastric cancer, endometrial cancer, melanoma, pancreatic cancer, liver cancer, kidney cancer, squamous cell carcinoma, ovarian cancer, sarcoma, osteosarcoma, thyroid cancer, bladder cancer, head and neck cancer, testicular cancer, ewing's sarcoma, rhabdomyosarcoma, medulloblastoma, neuroblastoma, cervical cancer, kidney cancer, urothelial cancer, vulval cancer, esophageal cancer, salivary gland carcinoma, nasopharyngeal cancer, buccal cancer, oral cancer, and GIST (gastrointestinal stromal tumor).

In another embodiment, the invention relates to a composition comprising a compound of formula (I) for use in treating a disease, syndrome, condition or disorder affected by inhibition of MALT1, selected from the group consisting of lymphoma, leukemia, cancer and a malignant neoplasm, such as non-hodgkin's lymphoma (NHL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), mucosa-associated lymphoma (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, hodgkin's lymphoma, burkitt's lymphoma, multiple myeloma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), fahrenheit, lymphoblastic macroglobulinemia, lymphocytic T-cell leukemia, Chronic Myelocytic Leukemia (CML), hairy cell leukemia, Acute lymphocytic T cell leukemia, plasmacytoma, immunoblastic large cell leukemia, megakaryocytic leukemia, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, brain (glioma), glioblastoma, breast cancer, colorectal/colon cancer, prostate cancer, lung cancer (including non-small cell lung cancer), gastric cancer, endometrial cancer, melanoma, pancreatic cancer, liver cancer, kidney cancer, squamous cell carcinoma, ovarian cancer, sarcoma, osteosarcoma, thyroid cancer, bladder cancer, head and neck cancer, testicular cancer, ewing's sarcoma, rhabdomyosarcoma, medulloblastoma, neuroblastoma, cervical cancer, kidney cancer, urothelial cancer, vulval cancer, esophageal cancer, salivary gland cancer, nasopharyngeal cancer, buccal cancer, oral cancer, and GIST (gastrointestinal stromal tumor).

In another embodiment, the invention relates to a composition comprising a compound of formula (I) for use in treating a disease, syndrome, condition or disorder affected by inhibition of MALT1, selected from diffuse large B-cell lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), and mucosa-associated lymphoid tissue (MALT) lymphoma.

One embodiment of the present invention relates to compositions comprising compounds of formula (I) for use in the treatment of immune diseases affected by inhibition of MALT1, including but not limited to autoimmune and inflammatory diseases, e.g., arthritis, inflammatory bowel disease, gastritis, ankylosing spondylitis, ulcerative colitis, pancreatitis, crohn's disease, celiac disease, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, gout, organ or transplant rejection, chronic allograft rejection, acute or chronic graft-versus-host disease, dermatitis (including atopic dermatitis), dermatomyositis, psoriasis, behcet's disease, uveitis, myasthenia gravis, grave's disease, hashimoto's thyroiditis, sjogren's syndrome, blistering disease, antibody-mediated vasculitis syndrome, immune complex vasculitis, allergic disease, inflammatory diseases, Asthma, bronchitis, Chronic Obstructive Pulmonary Disease (COPD), cystic fibrosis, pneumonia, pulmonary diseases (including edema, embolism, fibrosis, sarcoidosis, hypertension and emphysema, silicosis, respiratory failure, acute respiratory distress syndrome, BENTA disease, beryllium poisoning, and polymyositis).

In another embodiment, the invention relates to a composition comprising a compound of formula (I) for use in treating a disease, syndrome, condition or disorder affected by inhibition of MALT1, selected from Rheumatoid Arthritis (RA), psoriatic arthritis (PsA), psoriasis (Pso), Ulcerative Colitis (UC), crohn's disease, Systemic Lupus Erythematosus (SLE), asthma, and Chronic Obstructive Pulmonary Disease (COPD).

Another embodiment of the present invention relates to a pharmaceutical composition comprising a compound of formula (I).

Detailed Description

Embodiments of the invention include compounds of formula (I)

Wherein

AA)R₁Is independently selected from pyrazolo [1,5-a ]]Pyridin-4-yl and imidazo [1,2-a ]]Heteroaryl of pyridin-5-yl; wherein R is₁Optionally substituted independently with a substituent selected from chloro, aminocarbonyl and cyano;

BB)R₁is independently selected from (7-aminocarbonyl) pyrazolo [1,5-a]Pyridin-4-yl, (7-chloro) pyrazolo [1,5-a]Pyridin-4-yl, (7-cyano) pyrazolo [1,5-a]Pyridin-4-yl, (8-aminocarbonyl) imidazo [1,2-a]Pyridin-5-yl, (8-chloro) imidazo [1,2-a]Pyridin-5-yl, (8-cyano) imidazo [1,2-a]Pyridin-5-yl, (8-fluoro) imidazo [1,2-a]Heteroaryl of pyridin-5-yl;

CC)R₂is trifluoromethyl or methylsulfonyl;

DD)R₃independently selected from trifluoromethyl, cyano and chloro;

EE)R₃is trifluoromethyl;

FF)G₂is N;

GG)R₄independently selected from 2H-1,2, 3-triazol-2-yl, oxazol-2-yl, 4-methyloxaOxazol-2-yl, 5-methyloxazol-2-yl, 1H-pyrazol-1-yl, and tetrahydrofuran-2-yl;

HH)R₄independently selected from the group consisting of 1 (A), (B), (C^*R) -methoxyethyl, 1: (^*S) -methoxyethyl group, ((S) -methoxyethyl group)^*R) -tetrahydrofuran-2-yl and (^*S) -tetrahydrofuran-2-yl;

II)R₅is hydrogen, fluorine, chlorine, bromine or trifluoromethyl;

and any combination of the above embodiments AA) through II), provided that it is understood that combinatorial structures in which different embodiments of the same substituent are combined are excluded; so that in any case G₁And G₂Only one of them is N;

Embodiments of the invention include compounds of formula (I)

Wherein

R₂is trifluoromethyl or methylsulfonyl;

G₁is N or C (R)₄)；

R₃is trifluoromethyl;

R₄independently selected from triazolyl, 1- (methoxy) ethyl, oxazol-2-yl, 4-methyloxazol-2-yl, 5-methyloxazol-2-yl, 1H-pyrazol-1-yl, tetrahydrofuran-2-yl, CH₃SO₂-、(CH₃)₂S (═ O) (═ N) — and CH₃(NH＝)(O＝)S-；

R₅Independently selected from hydrogen, methyl, ethyl, fluoro, chloro, bromo, trifluoromethyl, methoxy and cyano;

R₆is hydrogen, methyl or trifluoromethyl;

R₇is hydrogen, methyl, ethyl or fluorine;

Another embodiment of the invention encompasses compounds of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt form thereof,

wherein

R₁Is independently selected from (7-aminocarbonyl) pyrazolo [1,5-a]Pyridin-4-yl, (7-chloro) pyrazolo [1,5-a]Pyridin-4-yl, (7-cyano) pyrazolo [1,5-a]Pyridin-4-yl, (8-methyl) imidazo [1,2-a]Pyridyl group, (8-aminocarbonyl) imidazo [1,2-a]Pyridin-5-yl, (8-chloro) imidazo [1,2-a]Pyridin-5-yl, (8-cyano) imidazo [1,2-a]Pyridin-5-yl, (8-fluoro) imidazo [1,2-a]Heteroaryl of pyridin-5-yl;

R₂is trifluoromethyl or methylsulfonyl;

G₁is N or C (R)₄)；

R₃is trifluoromethyl;

R₄independently selected from triazol-2-yl, pyrazol-1-yl, oxazol-2-yl, 4-methyloxazol-2-yl, 5-methyloxazol-2-yl, 1- (m-ethyl-1-methyl-2-yl)^*R) -methoxyethyl, 1: (^*S) -methoxyethyl group, ((S) -methoxyethyl group)^*R) -tetrahydrofuran-2-yl group, ((R) -tetrahydrofuran-2-yl group^*S) -tetrahydrofuran-2-yl, CH₃SO₂-、(CH₃)₂S (═ O) (═ N) — and CH₃(NH＝)(O＝)S-；

R₅Independently selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl and methoxy;

R₆is hydrogen;

R₇is hydrogen;

Further embodiments of the invention include compounds of formula (I) as defined herein, or enantiomers, diastereomers, solvates or pharmaceutically acceptable salt forms thereof, as exemplified in table 1 below.

TABLE 1：

In another embodiment, the invention relates to compounds of formula (I)

The compound is selected from:

5- (4- ((5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) carbamoyl) -5- (trifluoromethyl) -1H-pyrazol-1-yl) imidazo [1,2-a ] pyridine-8-carboxamide;

n- (5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (8-cyanoimidazo [1,2-a ] pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

n- (5-chloro-6- (1H-pyrazol-1-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

n- (6- (2H-1,2, 3-triazol-2-yl) -5- (trifluoromethyl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -N- (6- (methylsulfonyl) -5- (trifluoromethyl) pyridin-3-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

n- (5-chloro-6- (oxazol-2-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

n- (5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (8-methylimidazo [1,2-a ] pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

n- (5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -5- (methylsulfonyl) -1H-pyrazole-4-carboxamide;

n- (5-chloro-6- (5-methyloxazol-2-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

n- (5-chloro-6- (4-methyloxazol-2-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

1- (7-cyanopyrazolo [1,5-a ] pyridin-4-yl) -5- (trifluoromethyl) -N- (2- (trifluoromethyl) pyridin-4-yl) -1H-pyrazole-4-carboxamide;

4- (5- (trifluoromethyl) -4- ((2- (trifluoromethyl) pyridin-4-yl) carbamoyl) -1H-pyrazol-1-yl) pyrazolo [1,5-a ] pyridine-7-carboxamide;

n- (5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (7-cyanopyrazolo [1,5-a ] pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

1- (7-chloropyrazolo [1,5-a ] pyridin-4-yl) -5- (trifluoromethyl) -N- (2- (trifluoromethyl) pyridin-4-yl) -1H-pyrazole-4-carboxamide;

n- (5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (7-chloropyrazolo [1,5-a ] pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide

4- (4- ((5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) carbamoyl) -5- (trifluoromethyl) -1H-pyrazol-1-yl) pyrazolo [1,5-a ] pyridine-7-carboxamide;

(^*s) -N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (8-fluoroimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*r) -N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (8-chloroimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*r) -N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (8-fluoroimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*s) -N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (8-chloroimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*s) -N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (7-chloropyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*r) -N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (7-chloropyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*s) -N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (7-cyanopyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*r) -N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (7-cyanopyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*s) -N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (7-cyanopyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(. R) -N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (7-cyanopyrazolo [1,5-a ] pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*s) -N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (7-chloropyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*r) -N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (7-chloropyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

n- (6- ((dimethyl (oxo) -lambda)⁶-Thioalkylene) amino) -5-methylpyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

n- (6- ((dimethyl (oxo) -lambda)⁶-Thioalkylene) amino) -5- (trifluoromethyl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -N- (6- (S-methylsulfonylimino) -5- (trifluoromethyl) pyridin-3-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

n- (6- ((dimethyl (oxo) -lambda)⁶-Thioalkylene) amino) -5-fluoropyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

and

n- (5-chloro-6- ((dimethyl (oxo) -lambda)⁶-Thioalkylene) amino) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide

Or a pharmaceutically acceptable salt form thereof.

With respect to substituents, the term "independently" refers to the situation where when more than one substituent may be present, the substituents may be the same or different from each other.

The term "alkyl", whether used alone or as part of a substituent group, refers to a straight or branched carbon chain having from 1 to 8 carbon atoms. Thus, a specified number of carbon atoms (e.g. C)_1-8) Independently of the number of carbon atoms in the alkyl moiety or of the larger alkyl-containing substituentNumber of carbon atoms in the alkyl moiety. In the substituent having plural alkyl groups such as (C)_1-6Alkyl radical)₂In the amino group, C of the dialkylamino group_1-6The alkyl groups may be the same or different.

The term "alkoxy" refers to an-O-alkyl group, wherein the term "alkyl" is as defined above.

The terms "alkenyl" and "alkynyl" refer to straight and branched carbon chains having 2 to 8 carbon atoms in which the alkenyl chain contains at least one double bond and the alkynyl chain contains at least one triple bond.

The term "cycloalkyl" refers to a saturated or partially saturated, monocyclic or polycyclic hydrocarbon ring having from 3 to 14 carbon atoms. Examples of such rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and adamantyl.

The term "heterocyclyl" refers to a non-aromatic monocyclic or bicyclic ring system having 3 to 10 ring members comprising at least 1 carbon atom and 1 to 4 heteroatoms independently selected from N, O and S. Including non-aromatic cyclic rings having 5 to 7 members (where 1 to 2 members are N), or non-aromatic cyclic rings having 5 to 7 members (where 0, 1, or 2 members are N, and up to 2 members are O or S, and at least one member must be N, O or S) are included within the term heterocyclyl; wherein optionally the ring contains from 0 to 1 unsaturated bond, and optionally when the ring has 6 or 7 members, it contains up to 2 unsaturated bonds. The carbon atom ring members forming the heterocyclic ring may be fully saturated or partially saturated. The term "heterocyclyl" also includes two 5-membered monocyclic heterocycloalkyl groups bridged to form a bicyclic ring. Such groups are not considered to be fully aromatic and they are not referred to as heteroaryl groups. When the heterocyclic ring is bicyclic, both rings of the heterocyclic ring are non-aromatic and at least one of the rings contains a heteroatom ring member. Examples of heterocyclyl groups include, but are not limited to, pyrrolinyl (including 2H-pyrrolyl, 2-pyrrolinyl, or 3-pyrrolinyl), pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, and piperazinyl. Unless otherwise indicated, the heterocyclic ring is attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.

The term "aryl" refers to an unsaturated aromatic monocyclic or bicyclic ring having 6 to 10 carbon members. Examples of aromatic rings include phenyl and naphthyl.

The term "heteroaryl" refers to a monocyclic or bicyclic aromatic ring system having 5 to 10 ring members and containing carbon atoms and 1 to 4 heteroatoms independently selected from N, O and S. Aromatic rings having 5 or 6 members, wherein the ring consists of carbon atoms and has at least one heteroatom member, are included within the term heteroaryl. Suitable heteroatoms include nitrogen, oxygen, and sulfur. In the case of a 5-membered ring, the heteroaryl ring preferably contains one member of nitrogen, oxygen or sulfur, and in addition contains up to 3 additional nitrogens. In the case of a 6-membered ring, the heteroaryl ring preferably contains 1 to 3 nitrogen atoms. For the case where the 6-membered ring has 3 nitrogen atoms, up to 2 nitrogen atoms are adjacent. Examples of heteroaryl groups include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzothiadiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, and quinazolinyl groups. Unless otherwise indicated, the heteroaryl group is attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.

The term "halogen" or "halo" refers to fluorine, chlorine, bromine and iodine atoms.

The term "carboxy" refers to the group-C (═ O) OH.

The term "formyl" refers to the group-C (═ O) H.

The term "oxo" or "oxide" refers to a group (═ O).

When any of the terms "alkyl" or "aryl" or its prefix root appears in the name of a substituent (e.g., arylalkyl, alkylamino), that name should be interpreted to include that which is given above for "alkyl" and "aryl"These limitations are described. Specified number of carbon atoms (e.g. C)₁-C₆) Independently refers to the number of carbon atoms in the alkyl portion, the aryl portion, or the alkyl portion of the larger substituent in which the alkyl group appears at its prefix root. For alkyl and alkoxy substituents, the specified number of carbon atoms includes all of the individual members within the specified ranges. For example, C_1-6Alkyl groups individually include methyl, ethyl, propyl, butyl, pentyl, and hexyl, as well as subcombinations thereof (e.g., C_1-2、C_1-3、C_1-4、C_1-5、C_2-6、C_3-6、C_4-6、C_5-6、C_2-5Etc.).

Generally, under standard nomenclature used throughout this disclosure, the terminal portion of a given side chain is described first, followed by the adjacent functional group toward the point of attachment. Thus, for example, "C₁-C₆An alkylcarbonyl "substituent refers to a group represented by the formula:

the label "R" at a stereocenter indicates that the stereocenter has only the R-configuration, as defined in the art; likewise, the designation "S" means that the stereocenter has only the S-configuration. As used herein, the label "ar" or "ars" at the stereocenter is used to indicate that the stereocenter has a pure but unknown absolute configuration. As used herein, the label "RS" refers to a stereocenter that exists as a mixture of R-and S-configurations.

Compounds containing one stereocenter, not marked with a stereo bond, are mixtures of two enantiomers. Compounds containing two stereocenters not marked with a stereobond are mixtures of four diastereomers. A compound having two stereocenters, both labeled "RS" and underlined with a stereobond designation, is a mixture of two enantiomers with the relative stereochemistry as underlined. With uniform marks "^*RS' and two stereocenters marked with a stereobond identifier are compounds having a single but unknown phaseA mixture of two enantiomers of stereochemistry.

The unlabeled stereocenters not marked with a stereobond designation are a mixture of R-and S-configurations. For unlabeled stereocenters marked with a stereobond identifier, the relative and absolute stereochemistry is as recited.

Unless otherwise indicated, the definition of any substituent or variable at a particular position in a molecule is considered to be independent of its definitions elsewhere in that molecule. It is to be understood that substituents and substitution patterns on the compounds of the present invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and can be readily synthesized by techniques known in the art and those methods set forth herein.

The term "subject" refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.

The term "therapeutically effective amount" means that amount of active compound or pharmaceutical agent, including a compound of the invention, that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes reduction or inhibition of enzyme or protein activity, or amelioration of a symptom, alleviation of a disorder, slowing or delaying the progression of a disease, or prevention of a disease.

In one embodiment, the term "therapeutically effective amount" refers to an amount of a compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviate, inhibit, prevent and/or ameliorate a condition or disorder or disease (i) mediated by MALT 1; or (ii) is associated with MALT1 activity; or (iii) is characterized by activity (normal or abnormal) of MALT 1; or (2) reduces or inhibits the activity of MALT 1; or (3) reduces or inhibits expression of MALT 1; or (4) altering the protein level of MALT 1.

The term "composition" refers to a product comprising the specified ingredients in therapeutically effective amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

The term "MALT 1 mediated" refers to any disease, syndrome, condition or disorder that may occur in the absence of MALT1, but is capable of occurring in the presence of MALT 1. Suitable examples of MALT 1-mediated diseases, syndromes, conditions, or disorders include, but are not limited to, lymphomas, leukemias, carcinomas, and malignancies, such as non-hodgkin's lymphoma (NHL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, hodgkin's lymphoma, burkitt's lymphoma, multiple myeloma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), fahrenheit macroglobulinemia, lymphocytic T-cell leukemia, Chronic Myelogenous Leukemia (CML), hairy cell leukemia, acute lymphocytic T-cell leukemia, plasmacytoma, immunoblastic large cell leukemia, megakaryocytic leukemia, acute megakaryocytic leukemia, lymphoma, Promyelocytic leukemia, erythroleukemia, brain (glioma), glioblastoma, breast cancer, colorectal/colon cancer, prostate cancer, lung cancer (including non-small cell lung cancer), gastric cancer, endometrial cancer, melanoma, pancreatic cancer, liver cancer, kidney cancer, squamous cell carcinoma, ovarian cancer, sarcoma, osteosarcoma, thyroid cancer, bladder cancer, head and neck cancer, testicular cancer, ewing's sarcoma, rhabdomyosarcoma, medulloblastoma, neuroblastoma, cervical cancer, kidney cancer, urothelial cancer, vulval cancer, esophageal cancer, salivary gland carcinoma, nasopharyngeal cancer, buccal cancer, oral cancer, and GIST (gastrointestinal stromal tumor).

As used herein, the term "MALT 1 inhibitor" refers to an agent that inhibits or reduces at least one condition, symptom, disorder and/or disease of MALT 1.

As used herein, unless otherwise indicated, the terms "affect" or "affected" (which is affected by MALT1 inhibition when referring to a disease, syndrome, condition, or disorder) shall include a reduction in the frequency and/or severity of one or more symptoms or clinical manifestations of the disease, syndrome, condition, or disorder; and/or preventing the development of one or more symptoms or clinical manifestations of the disease, syndrome, condition or disorder or the development of the disease, syndrome or disorder.

As used herein, the terms "treating" or "treatment" of any disease, condition, syndrome, or disorder refers to ameliorating the disease, condition, syndrome, or disorder (i.e., slowing or arresting or slowing the development of at least one of the disease or its clinical symptoms). In another embodiment, "treating" or "treatment" refers to reducing or improving at least one physical parameter, including those that may not be discernible by the patient. In another embodiment, "treating" or "treatment" refers to modulating a disease, disorder, syndrome, or disorder that is physical (e.g., stabilizing a discernible symptom), physiological (e.g., stabilizing a physical parameter), or both. In another embodiment, "treating" or "treatment" refers to preventing or delaying the onset or development or progression of a disease, disorder, syndrome or disorder.

The compounds of the present invention are useful in methods for treating or ameliorating a disease, syndrome, condition or disorder affected by inhibition of MALT 1. Such methods comprise, consist of, and/or consist essentially of the steps of: administering a therapeutically effective amount of a compound of formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof to a subject, including animals, mammals and humans in need of such treatment, alleviation and/or prevention.

One embodiment of the present invention is directed to a method of treating a MALT 1-dependent or MALT 1-mediated disease or disorder in a subject in need thereof, including animals, mammals and humans in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I).

In another embodiment, the MALT 1-dependent or MALT 1-mediated disease or disorder is selected from cancers of hematopoietic origin or solid tumors, such as chronic myelogenous leukemia, myeloid leukemia, non-hodgkin's lymphoma and other B-cell lymphomas.

In particular, the compounds of formula (I) or enantiomers, diastereomers, solvates, or pharmaceutically acceptable salt forms thereof, are useful for treating or ameliorating diseases, syndromes, conditions, or disorders such as diffuse large B-cell lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), and mucosa-associated lymphoid tissue (MALT) lymphoma.

More specifically, the compounds of formula (I) or enantiomers, diastereomers, solvates or pharmaceutically acceptable salt forms thereof are useful for treating or ameliorating diffuse large B-cell lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL) and mucosa-associated lymphoid tissue (MALT) lymphoma comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt form thereof as defined herein.

Furthermore, the compounds of formula (I) or enantiomers, diastereomers, solvates or pharmaceutically acceptable salt forms thereof, are useful for treating or ameliorating an immune disease, syndrome, disorder or condition selected from Rheumatoid Arthritis (RA), psoriatic arthritis (PsA), psoriasis (Pso), Ulcerative Colitis (UC), crohn's disease, Systemic Lupus Erythematosus (SLE), asthma and Chronic Obstructive Pulmonary Disease (COPD).

Another embodiment of the present invention relates to compounds of formula (I)

Wherein

G₁is N or C (R)₄)；

R₄independently selected from triazolyl, 1- (methoxy) ethyl, oxazolyl, isoxazolyl, pyrazolyl, pyrrolyl, thiazolyl, tetrazolyl, oxadiazolyl and imidazolyl; wherein R is other than 1-methoxyethyl₄Optionally independently selected from oxo, C_1-4Alkyl, carboxyl, methoxycarbonyl, aminocarbonyl, hydroxymethyl, aminomethyl, (dimethylamino) methyl, amino, methoxymethyl, trifluoromethyl, amino (C)_2-4Alkyl) amino or cyano substituted with one or two substituents; or R₄Independently selected from tetrahydrofuran-2-yl, (CH)₃)₂S (═ O) (═ N) — and CH₃(NH ═) (O ═) S —; or when G is₂When is N, R₄Is hydrogen;

R₅independently selected from hydrogen, methyl, ethyl, chloro, bromo, trifluoromethyl, methylthio, methylsulfonyl, methoxy and cyano;

R₇is hydrogen, methyl, ethyl or fluorine;

Additional embodiments of the present invention include compounds of formula (I)

Wherein

BB)R₁is independently selected from (7-aminocarbonyl) pyrazolo[1,5-a]Pyridin-4-yl, (7-chloro) pyrazolo [1,5-a]Pyridin-4-yl, (7-cyano) pyrazolo [1,5-a]Pyridin-4-yl, (8-aminocarbonyl) imidazo [1,2-a]Pyridin-5-yl, (8-chloro) imidazo [1,2-a]Pyridin-5-yl, (8-cyano) imidazo [1,2-a]Pyridin-5-yl, (8-fluoro) imidazo [1,2-a]Heteroaryl of pyridin-5-yl;

CC)R₂is trifluoromethyl or methylsulfonyl;

DD)R₃independently selected from trifluoromethyl, cyano and chloro;

EE)R₃is trifluoromethyl;

FF)G₂is N;

GG)R₄independently selected from 2H-1,2, 3-triazol-2-yl, oxazol-2-yl, 4-methyloxazol-2-yl, 5-methyloxazol-2-yl, 1H-pyrazol-1-yl and tetrahydrofuran-2-yl; or when G is₂When is N, R₄Is hydrogen;

II)R₅is hydrogen, chlorine, bromine or trifluoromethyl;

Embodiments of the invention include compounds of formula (I)

Wherein

R₁Is independently selected from pyrazolo [1,5-a ]]Pyridyl and imidazo [1,2-a ]]Heteroaryl of pyridyl; wherein R is₁Optionally independently selected from methyl, ethylFluoro, chloro, cyano or aminocarbonyl;

R₂is trifluoromethyl or methylsulfonyl;

G₁is N or C (R)₄)；

R₃is trifluoromethyl;

R₄independently selected from triazolyl, 1- (methoxy) ethyl, oxazol-2-yl, 4-methyloxazol-2-yl, 5-methyloxazol-2-yl, 1H-pyrazol-1-yl, tetrahydrofuran-2-yl, (CH)₃)₂S (═ O) (═ N) — and CH₃(NH ═) (O ═) S —; or when G is₂When is N, R₄Is hydrogen;

R₅independently selected from hydrogen, methyl, ethyl, chloro, bromo, trifluoromethyl, methoxy and cyano;

R₆is hydrogen, methyl or trifluoromethyl;

R₇is hydrogen, methyl, ethyl or fluorine;

wherein

R₁Is independently selected from (7-aminocarbonyl) pyrazolo [1,5-a]Pyridin-4-yl, (7-chloro) pyrazolo [1,5-a]Pyridin-4-yl, (7-cyano) pyrazolo [1,5-a]Pyridin-4-yl, (8-aminocarbonyl) imidazo [1,2-a]Pyridin-5-yl, (8-chloro) imidazo [1,2-a]Pyridin-5-yl, (8-cyano) imidazo [1,2-a]Pyridin-5-yl, (8-fluoro) imidazo [1,2-a]Heteroaryl of pyridin-5-yl;

R₂is trifluoromethyl or methylsulfonyl;

G₁is N or C (R)₄)；

R₃is trifluoromethyl;

R₄independently selected from 1 (A), (B), (C), (^*R) -methoxyethyl, 1: (^*S) -methoxyethyl group, ((S) -methoxyethyl group)^*R) -tetrahydrofuran-2-yl and (^*S) -tetrahydrofuran-2-yl; or when G is₂When is N, R₄Is hydrogen;

R₆is hydrogen, methyl or trifluoromethyl;

R₇is hydrogen, methyl, ethyl or fluorine;

TABLE 1：

In another embodiment, the invention relates to compounds of formula (I)

The compound is selected from:

(^*s) -N- (5-chloro)-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (7-chloropyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

n- (6- ((dimethyl (oxo) -lambda)⁶Thioalkylene) amino) -5-fluoropyridin-3-yl) -1- (8-fluoroImidazo [1,2-a ]]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

n- (5-chloro-6- ((dimethyl (oxo) -lambda)⁶-Thioalkylene) amino) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

n- (6- ((dimethyl (oxo) -lambda)⁶-Thioalkylene) amino) -5-methoxypyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

and

or a pharmaceutically acceptable salt form thereof.

For use in medicine, the salts of the compounds of formula (I) are non-toxic "pharmaceutically acceptable salts". However, other salts may also be useful in the preparation of the compound of formula (I) or a pharmaceutically acceptable salt form thereof. Suitable pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts which may be formed, for example, by mixing a solution of the compound with a pharmaceutically acceptable acid solution such as hydrochloric, sulphuric, fumaric, maleic, succinic, acetic, benzoic, citric, tartaric, carbonic or phosphoric acid. Furthermore, if the compound of formula (I) contains an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, such as sodium or potassium salts; alkaline earth metal salts, such as calcium or magnesium salts; and salts formed with suitable organic ligands, such as quaternary ammonium salts. Thus, representative pharmaceutically acceptable salts include acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, dexcamphorsulfonate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, dedecyl propionate, ethanesulfonate, fumarate, glucoheptonate, gluconate, glutamate, para- α -hydroxyacetaminophenylarsonate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, methanesulfonate, methylbromide, methylnitrate, methylsulfate, mucate, naphthalenesulfonate, nitrate, potassium, sodium, potassium, sodium, potassium, Ammonium salts of N-methylglucamine, oleates, pamoates, palmitates, pantothenate, phosphates/diphosphates, polygalacturonates, salicylates, stearates, sulfates, subacetates, succinates, tannates, tartrates, theachlorates, tosylates, triethyliodides and valerates.

Representative acids and bases that can be used to prepare pharmaceutically acceptable salts include: acids, including acetic acid, 2-dichloroacetic acid, acetylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, (+) -camphoric acid, camphorsulfonic acid, (+) - (1S) -camphorsulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1, 2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucuronic acid, L-glutamic acid, alpha-oxo-glutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, (+) -L-lactic acid, (±) -DL-lactic acid, Lactobionic acid, maleic acid, (-) -L-malic acid, malonic acid, (±) -DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1, 5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+) -L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, and undecylenic acid; and bases including ammonia, L-arginine, benzphetamine, benzathine, calcium hydroxide, choline, dandol, diethanolamine, diethylamine, 2- (diethylamino) -ethanol, ethanolamine, ethylenediamine, N-methyl-glucamine, hydrabamine, 1H-imidazole, L-lysine, magnesium hydroxide, 4- (2-hydroxyethyl) -morpholine, piperazine, potassium hydroxide, 1- (2-hydroxyethyl) -pyrrolidine, sodium hydroxide, triethanolamine, tromethamine, and zinc hydroxide.

Embodiments of the present invention include prodrugs of compounds of formula (I). Generally, such prodrugs will be functional derivatives of the compounds which can be readily converted in vivo to the desired compounds. Thus, in the methods of the therapeutic or prophylactic embodiments of the present invention, the term "administering" encompasses treating or preventing the various diseases, conditions, syndromes and disorders described with or without the specifically disclosed compounds, but which are converted in vivo to the specified compounds upon administration to a patient. For example, a conventional procedure for selecting and preparing suitable prodrug derivatives is described in "Design of Prodrugs" (Design of Prodrugs) ", edited by H.Bundgaard, Elsevier (Escherweier), 1985.

Where compounds according to embodiments of the present invention have at least one chiral center, they may accordingly exist as enantiomers. If the compounds have two or more chiral centers, they may additionally exist in diastereomeric forms. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, certain crystalline forms of the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, certain compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of the present invention. The skilled person will understand that the term compound as used herein is intended to include solvated compounds of formula (I).

One of ordinary skill in the art will recognize that the compounds described herein may exist as tautomers, and that other tautomeric arrangements of the structures depicted herein are possible. It is to be understood that, even if not explicitly indicated, all tautomeric forms are to be understood as being encompassed by one structure, wherein one possible tautomeric arrangement of the compound groups is depicted.

When the processes for preparing compounds according to certain embodiments of the present invention produce mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared by enantiospecific synthesis or by resolution. For example, the compounds may be resolved into their component enantiomers by standard techniques, such as by formation of diastereomeric pairs by salt formation with an optically active acid (such as (-) -di-p-toluoyl-d-tartaric acid and/or (+) -di-p-toluoyl-l-tartaric acid), followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds can be resolved using a chiral HPLC column.

One embodiment of the present invention relates to a composition, including a pharmaceutical composition, comprising, consisting of, and/or consisting essentially of the (+) -enantiomer of a compound of formula (I), wherein the composition is substantially free of the (-) -isomer of the compound. Substantially free in the context of the present invention means less than about 25%, preferably less than about 10%, more preferably less than about 5%, even more preferably less than about 2%, and even more preferably less than about 1% of the (-) -isomer, calculated as follows:

another embodiment of the present invention is a composition, including pharmaceutical compositions, comprising, consisting of, and consisting essentially of the (-) -enantiomer of a compound of formula (I), wherein the composition is substantially free of the (+) -isomer of the compound. In the context of the present invention, substantially free means less than about 25%, preferably less than about 10%, more preferably less than about 5%, even more preferably less than about 2%, and even more preferably less than about 1% of the (+) -isomer calculated as follows:

within the scope of the present invention, any one or more elements (especially when mentioned in relation to the composition of formula (I)) is intended to comprise all isotopes or isotopic mixtures (naturally occurring or synthetically prepared) of said element in their natural abundance or in their isotopically enriched form. For example, references to hydrogen include within their scope¹H、²H, (D) and³h (T). Similarly, references to carbon and oxygen include within their scope¹²C、¹³C and¹⁴c and¹⁶o and¹⁸and O. Isotopes may be radioactive or non-radioactive. The radiolabeled compound of formula (I) may comprise a compound selected from³H、¹¹C、¹⁸F、¹²²I、¹²³I、¹²⁵I、¹³¹I、⁷⁵Br、⁷⁶Br、⁷⁷Br and⁸²one or more radioisotopes of Br. Preferably, the radioisotope is selected from²H、³H、¹¹C and¹⁸F。

during any of the processes used to prepare the compounds of the various embodiments of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any molecule of interest. This can be achieved using conventional protecting groups, such as those described in the following documents: protective Groups in Organic Chemistry (second edition), J.F.W.McOmie, Plenum Press, 1973; greene and p.g.m.wuts, Protective Groups in Organic Synthesis (Protective Groups in Organic Synthesis), John Wiley & Sons, 1991; and T.W.Greene and P.G.M.Wuts, Protective Groups in Organic Synthesis (third edition), John Wiley & Sons, 1999. The protecting group may be removed at a convenient subsequent stage using methods known in the art.

Although the compounds of the present embodiments (including pharmaceutically acceptable salts and pharmaceutically acceptable solvates thereof) may be administered alone, they are generally administered in admixture with a pharmaceutically acceptable carrier, pharmaceutically acceptable excipient and/or pharmaceutically acceptable diluent (selected according to the route of administration and standard pharmaceutical or veterinary practice). Accordingly, a particular embodiment of the present invention relates to pharmaceutical and veterinary compositions comprising a compound of formula (I) and at least one pharmaceutically acceptable carrier, pharmaceutically acceptable excipient and/or pharmaceutically acceptable diluent.

For example, in pharmaceutical compositions of embodiments of the present invention, a compound of formula (I) may be mixed with any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilizing agent(s), and combinations thereof.

Optionally, a solid oral dosage form (e.g., a tablet or capsule) containing a compound of the invention may be administered in at least one dosage form at a time. The compounds may also be administered in sustained release formulations.

Additional oral dosage forms in which the compounds of the present invention may be administered include elixirs, solutions, syrups and suspensions; each dosage form optionally contains flavoring and coloring agents.

Alternatively, the compounds of formula (I) may be administered by inhalation (intratracheal or intranasal) or in the form of suppositories or pessaries, or they may be administered topically in the form of lotions, solutions, creams, ointments or dusting powders. For example, they may be incorporated into a cream comprising, consisting of and/or consisting essentially of an aqueous emulsion of polyethylene glycol or liquid paraffin. They may also be incorporated into an ointment comprising, consisting of, and/or consisting essentially of a wax or soft paraffin base and any stabilizers and preservatives as may be desired at a concentration of between about 1% to about 10% by weight of the ointment. Alternative means of administration include transdermal administration by use of a skin patch or transdermal patch.

The pharmaceutical compositions of the invention (as well as the compounds of the invention alone) may also be injected parenterally, for example intracavernosally, intravenously, intramuscularly, subcutaneously, intradermally or intrathecally. In such a case, the composition will also include at least one of a suitable carrier, a suitable excipient, and a suitable diluent.

For parenteral administration, the pharmaceutical compositions of the present invention are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts and monosaccharides to make the solution isotonic with blood.

For buccal or sublingual administration, the pharmaceutical compositions of the invention may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

By way of further example, a pharmaceutical composition containing at least one of the compounds of formula (I) as an active ingredient may be prepared by mixing one or more compounds with a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, and/or a pharmaceutically acceptable excipient according to conventional pharmaceutical mixing techniques. The carriers, excipients, and diluents can take a wide variety of forms depending on the desired route of administration (e.g., oral, parenteral, etc.). Thus for liquid oral preparations such as suspensions, syrups, elixirs and solutions, suitable carriers, excipients and diluents include water, glycols, oils, alcohols, flavoring agents, preservatives, stabilizers, coloring agents and the like; for solid oral formulations such as powders, capsules and tablets, suitable carriers, excipients and diluents include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. The solid oral dosage form may also optionally be coated with a substance such as sugar, or enteric coated, in order to regulate the major site of absorption and disintegration. For parenteral administration, carriers, excipients, and diluents typically include sterile water, and other ingredients may be added to increase the solubility and preservability of the composition. Injectable suspensions or solutions may also be prepared using aqueous carriers and appropriate additives such as solubilizers and preservatives.

A therapeutically effective amount of a compound of formula (I) or a pharmaceutical composition thereof comprises from about 0.1mg to about 3000mg, or any specific amount or range therein, specifically from about 1mg to about 1000mg, or any specific amount or range therein, or more specifically from about 10mg to about 500mg, or a dosage range therein, of the active ingredient in a dosing regimen of about 1 to about 4 times daily on average (70kg) of a human; however, it will be apparent to those skilled in the art that: the therapeutically effective amount of the compound of formula (I) will vary with the disease, syndrome, condition and disorder being treated.

For oral administration, the pharmaceutical composition is preferably provided in the form of a tablet containing about 1.0, about 10, about 50, about 100, about 150, about 200, about 250 and about 500 milligrams of the compound of formula (I).

One embodiment of the present invention relates to a pharmaceutical composition for oral administration comprising a compound of formula (I) in an amount from about 25mg to about 500 mg.

Advantageously, the compound of formula (I) may be administered in a single daily dose, or the total daily dose may be administered in divided doses of two, three and four times daily.

The optimal dosage of the compound of formula (I) to be administered can be readily determined and will vary with the particular compound used, the mode of administration, the strength of the preparation, and the course of the disease, syndrome, condition or disorder. In addition, factors associated with the particular subject being treated, including subject sex, age, weight, diet and time of administration, will result in the need to adjust the dosage to achieve the appropriate level of treatment and the desired therapeutic effect. Thus, the above dosages are exemplary of the general case. Of course, there may be individual instances where a higher or lower dosage range is beneficial, and such instances are within the scope of this invention.

The compound of formula (I) may be administered in any of the compositions and dosing regimens described above, or with the aid of those compositions and dosing regimens that are established in the art, so long as the use of the compound of formula (I) is required by the subject in need thereof.

In one embodiment, cancers that may benefit from treatment with MALT1 inhibitors of the invention include, but are not limited to, lymphomas, leukemias, carcinomas, and malignancies, e.g., non-hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, hodgkin's lymphoma, burkitt's lymphoma, multiple myeloma, Chronic Lymphocytic Leukemia (CLL), lymphocytic T-cell leukemia, Chronic Myelogenous Leukemia (CML), hairy cell leukemia, acute lymphocytic T-cell leukemia, plasmacytoma, immunoblastic large cell leukemia, megakaryocytic leukemia, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, brain (glioma), Glioblastoma, breast cancer, colorectal/colon cancer, prostate cancer, lung cancer (including non-small cell lung cancer), gastric cancer, endometrial cancer, melanoma, pancreatic cancer, liver cancer, kidney cancer, squamous cell carcinoma, ovarian cancer, sarcoma, osteosarcoma, thyroid cancer, bladder cancer, head and neck cancer, testicular cancer, ewing's sarcoma, rhabdomyosarcoma, medulloblastoma, neuroblastoma, cervical cancer, kidney cancer, urothelial cancer, vulval cancer, esophageal cancer, salivary gland carcinoma, nasopharyngeal cancer, buccal cavity cancer, oral cavity cancer, and GIST (gastrointestinal stromal tumor).

In another embodiment, inhibitors of MALT1 of the present invention may be used to treat immune diseases including, but not limited to, autoimmune and inflammatory diseases, such as arthritis, inflammatory bowel disease, gastritis, ankylosing spondylitis, ulcerative colitis, pancreatitis, crohn's disease, celiac disease, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, gout, organ or transplant rejection, chronic allograft rejection, acute or chronic graft-versus-host disease, dermatitis (including atopic dermatitis), dermatomyositis, psoriasis, behcet's disease, uveitis, myasthenia gravis, grave's disease, hashimoto's thyroiditis, sjogren's syndrome, blistering disease, antibody-mediated vasculitis syndrome, immune complex vasculitis, allergic disease, asthma, bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Cystic fibrosis, pneumonia, lung diseases (including edema, embolism, fibrosis, sarcoidosis, hypertension and emphysema, silicosis, respiratory failure, acute respiratory distress syndrome, BENTA disease, beryllium poisoning, and polymyositis).

In another embodiment of the invention, the compounds of the invention may be used in combination with one or more other agents, more specifically, in combination with other anti-cancer agents, such as chemotherapeutic agents, antiproliferative agents, or immunomodulators, or in combination with adjuvants in the treatment of cancer, such as immunosuppressive or anti-inflammatory agents.

Possible combinations of compounds of the invention may include, but are not limited to, BTK (bruton's tyrosine kinase) inhibitors such as ibrutinib, SYK inhibitors, PKC inhibitors, PI3K pathway inhibitors, BCL family inhibitors, JAK inhibitors, PIM kinase inhibitors, rituximab, or other B cell antigen binding antibodies, as well as immune cell redirecting agents (e.g., bornatemab or CAR T cells) and immune modulating agents such as daratumab, anti-PD 1 antibodies, and anti-PD-L1 antibodies.

It has been found that the compounds of the present invention inhibit MALT1 activity.

In some embodiments, inhibition of MALT1 by a provided compound is useful for treating or preventing (particularly treating) a non-limiting list of cancers described herein.

The present invention relates to compounds of formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt form thereof, for use as a medicament.

The present invention relates to compounds of formula (I) or enantiomers, diastereomers, solvates, or pharmaceutically acceptable salt forms thereof, for use in inhibiting MALT1 activity.

The present invention relates to compounds of formula (I) or enantiomers, diastereomers, solvates or pharmaceutically acceptable salt forms thereof, for use in the treatment of the diseases mentioned herein.

The present invention relates to compounds of formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt form thereof, for use in the treatment or prophylaxis, in particular treatment, of such diseases.

The present invention relates to compounds of formula (I) or enantiomers, diastereomers, solvates, or pharmaceutically acceptable salt forms thereof, for use in the treatment or prevention, particularly treatment, of a disease or condition mediated by MALT 1.

The present invention relates to compounds of formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt form thereof, for use in the preparation of a medicament.

The present invention relates to compounds of formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt form thereof, for use in the preparation of a medicament for inhibiting MALT 1.

The present invention relates to compounds of formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt form thereof, for use in the preparation of a medicament for the treatment or prevention, in particular for the treatment, of any one of the diseases or conditions mentioned herein.

The present invention relates to compounds of formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt form thereof, for use in the preparation of a medicament for the treatment of any one of the diseases or conditions mentioned herein.

The present invention relates to compounds of formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt form thereof, for use in the treatment or prevention of any one of the diseases mentioned herein, which may be administered to a mammal, preferably a human.

According to the utility of a compound of formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt form thereof, there is provided a method of treating warm-blooded animals (including humans) suffering from any one of the diseases mentioned herein or a method of preventing warm-blooded animals (including humans) from suffering from any one of the diseases mentioned herein.

General synthetic method

Representative compounds of the invention can be synthesized according to the general synthetic methods described below and illustrated in the schemes and examples that follow. As the schemes are illustrative, the invention should not be construed as being limited to the chemical reactions and conditions in the schemes and examples. Compounds analogous to these exemplified target compounds can be prepared by similar routes. The disclosed compounds may be used as medicaments as described herein. The different starting materials used in the schemes and examples are commercially available or can be prepared by methods well known to those skilled in the art.

Abbreviations used in the present specification, particularly in the schemes and examples, are as follows:

ACN acetonitrile

AcOH acetic acid

BINAP 2,2 '-bis (diphenylphosphino) -1, 1' -dinaphthylene

Boc carbamic acid tert-butyl ester

BuLi butyl lithium

Cbz Carboxylic acid benzyl ester

DCM dichloromethane

DMA dimethyl acetamide

DME ethylene glycol dimethyl ether

DMF dimethyl formamide

DMSO dimethyl sulfoxide

EA Ethyl acetate

Et Ethyl group

Et₂O Ether

EtOAc ethyl acetate

EtOH ethanol

FCC flash column chromatography

h hours

HATU O- (7-azabenzotriazol-1-yl) -N, N, N ', N' -tetramethyluronium hexafluorophosphate

HCHO Formaldehyde

HCl hydrochloric acid

HPLC high performance liquid chromatography

KCN potassium cyanide

LCMS high-pressure liquid chromatography-mass spectrometry

LDA lithium diisopropylamide

LiOH lithium hydroxide

Me methyl group

MeCN acetonitrile

MeOH methanol

mg of

min for

NaCN sodium cyanide

NaOH sodium hydroxide

NaOtBu tert-butyl sodium alcoholate

NH₄Cl ammonium chloride

Pd/C palladium on carbon

Pd₂(dba)₃Tris (dibenzylideneacetone) dipalladium

Pd(dppf)Cl₂[1, 1' -bis (diphenylphosphino) ferrocene]Palladium dichloride

Pd(OAc)₂Palladium diacetate

Pd(PPh₃)₄Tetrakis (triphenylphosphine) palladium

PPh₃Triphenylphosphine

p-TsOH p-toluenesulfonic acid

RT or RT Room temperature

TBAF tetrabutylammonium fluoride

TMSI iodotrimethylsilane

t-Bu tert-butyl

TFA trifluoroacetic acid

TFAA trifluoroacetic anhydride

THF tetrahydrofuran

TLC thin layer chromatography

Xantphos 4, 5-bis diphenylphosphine-9, 9-dimethylxanthene

Xphos 2-dicyclohexylphosphino-2 ', 4 ', 6 ' -triisopropylbiphenyl

A compound of formula (Ia)Can be prepared according to the process shown in scheme 1, wherein R₇Is hydrogen.

Scheme 1

The carboxylic acid of formula (1A) can be treated with carbonyldiimidazole and then the malonic acid monoester of formula (1B) and a base such as isopropyl magnesium chloride are added to give the ketoester of formula (1C) wherein R' is C_1-4An alkyl group. Condensation with triethyl orthoformate or with 1, 1-dimethoxy-N, N-dimethylmethylamine in acetic anhydride can produce the 2-ethoxymethylene-3-oxo ester (or 2- ((dimethylamino) methylene-3-oxo ester) of formula (1D.) hydrolysis of the ester group of formula (1D) can be treated with hydrazine of formula (1E) to provide the pyrazole of formula (1F.) the hydrolysis of the ester group can be achieved by treatment with aqueous sodium hydroxide in the presence of an alcoholic cosolvent to provide the corresponding carboxylic acid intermediate, which can then be converted to the compound of formula (I) upon amide coupling with the compound of formula (1G.) the amide coupling can be carried out in the presence of phosphorus oxychloride in pyridine, for example, to give the corresponding acid chloride, followed by treatment with the compound of formula (1G) in the presence of a base, hi one embodiment, the amide coupling reaction is carried out in the presence of a suitable amide coupling reagent such as HATU, in the presence of a base such as, but not limited to, diisopropylethylamine.

Alternatively, the pyrazole ester of formula (1F) can be converted directly to the compound of formula (I) by treatment with a compound of formula (1G) and a base such as potassium tert-butoxide.

Scheme 2 shows that₇An alternative route to the compound of formula (Ia) which is hydrogen.

Scheme 2

Aniline (1G) can be coupled with lithium acetoacetate of formula (2A) in the presence of a coupling agent such as BOP, a base such as DIPEA, and a solvent such as NMP to give a compound of formula (2B). The compound of formula (2B) may then be reacted with DMF-DMA (2C) in the presence of an acid such as TsOH, or with triethoxymethane (2D) in AcOH to give a compound of formula (2E) or (2F), respectively. The compound of formula (2E) or (2F) may then be treated with a hydrazine of formula (1E) to provide the compound of formula (I).

Scheme 3 shows the preparation of certain hydrazine intermediates of formula (1E) which are useful in the preparation of compounds of formula (I) of the present invention.

Scheme 3

The heteroarylamine of formula (3B) may be converted to a heteroaryldiazonium salt by treatment with sodium nitrite under acidic conditions. This intermediate can be reduced using a reducing agent such as tin (II) chloride or ascorbic acid to form the hydrazine of formula (1E). For the non-commercially available heteroarylamines of formula (3B), they can be obtained by reducing the heteronitroarene (3A) using hydrogen and Pt/C or other conventional nitro-reduction conditions (scheme 1).

In the presence of a ligand such as Xantphos and a base such as sodium tert-butoxide₁Substituted chlorides, bromides and iodides may undergo palladium catalyzed Buchwald Hartwig coupling with benzophenone hydrazine to form hydrazines of formula (3D). Acid hydrolysis can yield a hydrazine of formula (1E) (scheme 2).

R₁Substituted boronic acids may also be used as precursors to compounds of formula (1E) via the routes shown in scheme 3. Boronic acids of formula (3E) may be Cu2+ catalysed (such as Cu (OAc)₂，CH₂Cl₂TEA in (b) with di-tert-butyl azodicarboxylate to give an intermediate of formula (3F), which can be deprotected under acidic conditions to give a compound of formula (1E). Heteroarylhydrazines of formula (1E-1) having a nitrogen atom in the ortho or para position relative to the hydrazine functional group can be prepared by direct replacement of the halogen with hydrazine or hydrazine hydrate. The non-commercially available (hetero) halogenated aromatics of formula (3G) can be prepared by forming the N-oxides from their corresponding (hetero) aromatics (3I) with an oxidizing agent such as mCPBA(3J) (or (3K)), which may then be treated with POCl₃And DMF, POBr₃the/DMF, TFAA/TBAF or TMSI treatment (scheme 4) converts it to the (hetero) haloarene 3G. Alternatively, the halo (hetero) arene of formula (3H) can undergo palladium-catalyzed cross-coupling with hydrazine to provide intermediate (1E-2) directly (path 5).

Scheme 4 shows various routes that can be used to synthesize intermediate (1G-1), where G₁Is C (R)₄)。

Scheme 4

The compound (B-1) may be in the presence of a base such as Cs₂CO₃In a solvent such as DMF, with a compound of formula R₄H to give a compound of formula (4B). Alternatively, the compound of formula (4C) may be cross-coupled with a cross-coupling reagent such as a boron reagent of formula (4D) or formula R₄Sn(Bu)_3--In the presence of a palladium catalyst including, but not limited to, Pd (dppf) Cl₂Or Pd (PPh)₃)₄Treatment in a suitable solvent or solvent system such as DMF, dioxane/water and the like affords compounds of formula (4B). Another suitable route comprises reacting a compound of formula (4C) with a compound of formula R₄Compounds of H with bases such as Cs in the presence of coupling reagents such as CuI₂CO₃Reaction in a solvent such as DMF affords the compound of formula (4B). Can be in NH₄The compound of formula (4B) is reduced to the compound of formula (1G-1) using a reducing agent such as Zn or Fe in the presence of Cl in a solvent such as MeOH.

Scheme 5 illustrates the preparation of certain compounds of formula (I) wherein R₆Is not hydrogen.

Scheme 5

Scheme 6 shows intermediate (1G-1)) In which G is₁Is C (R)₄) And R is₄＝(CH₃)₂SONH, X is Cl, Br, I.

Scheme 6

Aniline (6A) can be reacted with acetic anhydride in the presence of a solvent such as DCM at 100 ℃ or at room temperature to give compound 6B. In the presence of ligands such as 4, 5-bis (diphenylphosphino) -9, 9-dimethylxanthene and bases such as Cs₂CO₃Compound 6B can undergo palladium catalyzed Buchwald-Hartwig coupling with S, S-dimethyl sulfoximine in the presence of a suitable solvent such as dioxane to form compound 6C. Compound 6C can be deprotected to compound 1G-1 in the presence of a base such as KOH in a suitable solvent such as EtOH.

Scheme 7 shows the synthesis of formula 7B, wherein R₄Is S (═ NH) (O) Me.

Scheme 7

Hydrolysis of compound 1F can be achieved by treatment with aqueous sodium hydroxide in the presence of an alcoholic cosolvent to provide the corresponding carboxylic acid intermediate, which can then be converted to compound 7A upon amide coupling with a compound of formula (1G-2). The amide coupling can be carried out in the presence of, for example, phosphorus oxychloride in pyridine to give the corresponding acid chloride, which is then treated with a compound of formula (1G-2) in the presence of a base such as pyridine. In oxidizing agents such as PhI (OAc)₂Compound 7A can be reacted with ammonium carbamate in the presence of a suitable solvent such as MeOH to provide compound 7B.

DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION

In the following examples, some of the synthesis products which have been isolated as residues are listed. One of ordinary skill in the art will appreciate that the term "residue" does not limit the physical state of the product as it is isolated, and can include, for example, solids, oils, foams, gums, slurries, and the like.

Example 1

5- (4- ((5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) carbamoyl) -5- (trifluoromethyl) -1H-pyrazol-1-yl) imidazo [1,2-a ] pyridine-8-carboxamide, compound 1

A.2-amino-6-chloronicotinamide, Compound 1a

HATU (1.65g, 4.35mmol) was added to a solution of 2-amino-6-chloronicotinic acid (500mg, 2.90mmol), ammonium chloride (155mg, 2.90mmol), DIEA (1.87g, 14.49mmol) in dichloromethane (8 mL). The mixture was stirred at room temperature for 2 hours. The reaction mixture was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate 1:0 to ethyl acetate). The desired fractions were collected and the solvent was concentrated under reduced pressure to give the title compound as a yellow solid (450mg, 90.5%).

B.5-Chloroimidazo [1,2-a ]]Pyridine-8-carboxamides, Compound 1b

2-bromo-1, 1-diethoxyethane (1.03g, 5.25mmol) was added to a solution of 2-amino-6-chloronicotinamide (540mg, 2.62mmol) in HBr (2mL) and ethanol (20 mL). The mixture was stirred at room temperature for 2 hours. The solvent was concentrated under reduced pressure. To the mixture was added water (20 mL). The mixture was extracted with EtOAc (30 mL. times.3). The combined organic layers were washed with brineWashing with anhydrous MgSO₄Dried and then filtered. The filtrate was concentrated under reduced pressure to give the title compound (460mg, 89.7% yield).

C.5-hydrazinoimidazo [1, 2-a)]Pyridine-8-carboxamides, Compound 1c

Hydrazine (672mg, 20.96mmol) was added to a solution of 5-chloroimidazo [1,2-a ] pyridine-8-carboxamide (410mg, 2.10mmol) in ethanol (20 mL). The reaction mixture was stirred at 80 ℃ for 16 hours. The solvent was concentrated under reduced pressure to give the crude product, which was used in the next step without further purification.

E.1- (8-carbamoylimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid Ethyl ester, Compound 1d

Ethyl 2- (ethoxymethylene) -4,4, 4-trifluoro-3-oxobutanoate (1.51g, 6.28mmol) was added to 5-hydrazinoimidazo [1,2-a ]]Pyridine-8-carboxamide (600mg, 3.14mmol) in ethanol (20 mL). The mixture was reacted at 80 ℃ for 3 hours. The solvent was concentrated under reduced pressure to give the crude product as a brown oil. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate). The desired fractions were collected and the solvent was concentrated under reduced pressure to give the product as a yellow solid (180mg, 14%). LC-MS (ES, M/z) [ M +1 ]]⁺368.0。

F.1- (8-carbamoylimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid, compound 1e

Lithium hydroxide (9.78mg, 0.41mmol) was added to 1- (8-carbamoylimidazo [1,2-a ]]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid ethyl ester (100mg, 0.27mmol) in THF/water (4mL, 1: 1). The mixture was reacted at room temperature for 72 hours. The solvent was concentrated under reduced pressure, and water (10mL) was added to the mixture. The mixture was adjusted to acidity (pH 5) by adding 1M hydrochloric acid, and then extracted with ethyl acetate (20mL × 3). The combined organic layers were washed with brine, over anhydrous MgSO₄Drying, filtration and concentration of the filtrate under reduced pressure gave the title compound as a brown oil (90mg, 69.6%). LC-MS (ES, M/z) [ M +1 ]]⁺340.0

G.3-chloro-5-nitro-2- (2H-1,2, 3-triazol-2-yl) pyridine, 1g

2, 3-dichloro-5-nitropyridine (50g, 259.08mmol), 1H-1,2, 3-triazole (19.683g, 284.99mmol), potassium carbonate (46.549g, 336.81mmol) and CH₃A mixture of CN (200mL) was heated to 40 ℃ and stirred overnight. Ethyl acetate (500mL) was added. The mixture was washed with water (500 mL. times.2) and brine (500mL) over anhydrous Na₂SO₄Dried, filtered and concentrated to dryness under reduced pressure. The residue was triturated with DCM (100mL), filtered and the solid collected to give compound 1g (40g, 68%) as an off-white solid. LC-MS (ES, m/z): [ M +1 ]]⁺225.9。¹H NMR(400MHz,DMSO-d₆)δppm 9.40(d,J＝2.0Hz,1H),9.15(d,J＝2.0Hz,1H),8.33(s,2H)。

H.5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-amine, 1H

3-chloro-5-nitro-2- (2H-1,2, 3-triazol-2-yl) pyridine (20g, 88.656mmol), MeOH (500mL), and Pt/C (2g, 5%, 0.513mmol) were added to 1000mLHydrogenation reaction flask. The resulting mixture is reacted in H₂The mixture was stirred under an atmosphere (30psi) at 25 ℃ for 20 hours. The suspension was filtered through a pad of celite and the filter cake was washed with ethyl acetate (100 mL). The filtrate was concentrated to dryness under reduced pressure to give the crude product, which was purified by preparative reverse phase HPLC (0% to 50% (v/v) CH₃CN and containing 0.05% NH₃Water) and then lyophilized to dryness to give compound 1h (10.4g, 60%) as an off-white solid. LC-MS (ES, m/z): [ M +1 ]]⁺196.1；¹H NMR(400MHz,DMSO-d₆)δppm 8.05(s,2H),7.83(d,J＝2.0Hz,1H),7.21(d,J＝2.4Hz,1H),6.19(s,2H)。

5- (4- ((5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) carbamoyl) -5- (trifluoromethyl) 1H-pyrazol-1-yl) imidazo [1,2-a]Pyridine-8-carboxamides, Compound 1

Adding POCl₃(29.08mg, 0.19mmol) was added to 1- (8-carbamoylimidazo [1,2-a ]]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid (90mg, 0.19mmol), 5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-amine (44.51mg, 0.23mmol) and pyridine (30.0mg, 0.38mmol) in a mixture of methylene chloride (6 mL). The reaction mixture was stirred at 20 ℃ for 1 h. Adding saturated NaHCO₃(solution) (20mL) was added to the mixture. Subjecting the mixture to CH₂Cl₂(20 mL. times.2). The combined organic layers were washed with brine. The organic layer was concentrated under reduced pressure to give the crude product as a brown oil. The crude product was purified by preparative high performance liquid chromatography: column: phenomenex Gemini 150 × 25mm × 10 um; conditions are as follows: a: water (0.05% ammonium hydroxide v/v); b: MeCN, start with: a (85%) and B (15%); and (4) at the end: a (55%) and B (45%). Gradient time (min) 12; 100% B hold time (min) 2.2; flow rate (ml/min) 25. The purified fractions were collected and the organic solvent was concentrated under reduced pressure. The aqueous layer was lyophilized to dryness to give the product (30mg, 30.5%) as a white solid.¹H NMR(400MHz,DMSO-d6)δppm 7.61-7.67(2H,m),7.88(1H,d,J＝1.25Hz),8.21(2H,s),8.23(1H,s),8.27(1H,br s),8.69(1H,d,J＝2.26Hz),8.76(1H,s),8.86(1H,d,J＝2.01Hz),9.43(1H,br s),11.32(1H,br s)。LC-MS:(ES,m/z):[M+1]⁺517.1

As those skilled in the art will readily recognize, following the procedure described in example 1, the appropriate reagents, starting materials and purification methods were selected and replaced, and the reaction temperature, reaction time and other variables or parameters were adjusted as needed or desired, to prepare the following compounds (2-7).

Example 2

N- (5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (8-cyanoimidazo [1,2-a ] pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, compound 2

¹H NMR(400MHz,DMSO-d₆)δppm 7.70(1H,d,J＝7.53Hz),7.74(1H,d,J＝1.00Hz),7.92(1H,s),8.20(2H,s),8.29(1H,d,J＝7.53Hz),8.68(1H,d,J＝2.26Hz),8.78(1H,s),8.86(1H,d,J＝2.26Hz),11.32(1H,br s)。LC-MS:(ES,m/z):[M+1]⁺499.1

Example 3

N- (5-chloro-6- (1H-pyrazol-1-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, compound 3

¹H NMR(400MHz,DMSO-d6)δppm 6.50-6.61(m,1H),7.42-7.52(m,2H),7.53-7.56(m,1H),7.80(dd,J＝9.0,1.0Hz,2H),8.25(d,J＝2.4Hz,1H),8.58(d,J＝2.2Hz,1H),8.70(s,1H),8.78(d,J＝2.2Hz,1H),10.78(dt,J＝9.8,1.8Hz,1H)。LC-MS:(ES,m/z):[M+1]⁺490.9

Example 4

N- (6- (2H-1,2, 3-triazol-2-yl) -5- (trifluoromethyl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 4

¹H NMR(400MHz,DMSO-d6)δppm 7.41-7.47(1H,m),7.48-7.52(1H,m),7.54(1H,d,J＝2.20Hz),7.77(1H,s),8.20(2H,s),8.72(1H,s),8.88(1H,d,J＝2.20Hz),9.17(1H,d,J＝1.96Hz),11.40(1H,br s)。LC-MS:(ES,m/z):[M+1]⁺526.1

Example 5

1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -N- (6- (methylsulfonyl) -5- (trifluoromethyl) pyridin-3-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, compound 5

¹H NMR(400MHz,DMSO-d6)δδppm 3.47(3H,s),7.43-7.49(1H,m),7.50-7.54(1H,m),7.54-7.57(1H,m),7.79(1H,d,J＝1.25Hz),8.71(1H,s),8.83(1H,d,J＝2.01Hz),9.24(1H,d,J＝2.01Hz),11.49(1H,br s)。LC-MS:(ES,m/z):[M+1]⁺537.1

Example 6

N- (5-chloro-6- (oxazol-2-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, compound 6

¹H NMR(400MHz,DMSO-d6)δδppm 7.41-7.56(m,4H),7.78(s,1H),8.34(s,1H),8.56(d,J＝1.7Hz,1H),8.70(s,1H),8.94(d,J＝1.7Hz,1H),11.24(br s,1H)。LC-MS:(ES,m/z):[M+1]⁺492.1

Example 7

N- (5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (8-methylimidazo [1,2-a ] pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 7

¹H NMR(400MHz,DMSO-d6)δppm 2.59(3H,s),7.30(2H,d,J＝3.67Hz),7.32(1H,s),7.66(1H,s),8.16(2H,s),8.64(1H,d,J＝2.20Hz),8.66(1H,s),8.82(1H,d,J＝2.20Hz),11.30(1H,br s)。LC-MS:(ES,m/z):[M+1]⁺488.1

Example 8

N- (5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -5- (methylsulfonyl) -1H-pyrazole-4-carboxamide, compound 8

A.5-amino-1- (6-bromo-5-fluoropyridin-2-yl) -1H-pyrazole-4-carboxylic acid ethyl ester, Compound 8a

A solution consisting of 2-bromo-3-fluoro-6-hydrazinopyridine (3.8g, 18.45mmol) and ethyl 2-cyano-3-ethoxyacrylate (4.68mg, 27.67mmol) in ethanol (50mL) was stirred at 80 ℃ for 3 hours. The resulting solution was cooled to room temperature and concentrated to dryness under reduced pressure to give the crude title product. The crude product is purified by flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate 100/0 to 30/70). The eluent was collected and the solvent was concentrated under reduced pressure to give the product as a white solid (1.7g, 25.3%).¹H NMR(400MHz,DMSO-d6)δppm 1.14-1.24(m,3H),4.10(q,J＝7.09Hz,2H),6.53-6.72(m,1H),7.58-7.74(m,1H),7.77-8.04(m,1H),9.27-9.56(m,1H),10.11-10.43(m,1H)。LC-MS:(ES,m/z):[M+1]⁺331.0

B.5-amino-1- (6- ((tert-butoxycarbonyl) amino) -5-fluoropyridin-2-yl) -1H-pyrazole-4-carboxylic acid ethyl ester, compound 8b

In N₂Palladium diacetate (122.8mg, 0.55mmol) and (9, 9-dimethyl-9H-xanthene-4, 5-diyl) bis (diphenylphosphine) (158.2mg, 0.27mmol) were added to a solution of ethyl 5-amino-1- (6-bromo-5-fluoropyridin-2-yl) -1H-pyrazole-4-carboxylate (0.90g, 2.74mmol), tert-butyl carbamate (384.4mg, 3.28mmol) and cesium carbonate (1782mg, 5.47mmol) in dioxane (10mL) with bubbling. The reaction was stirred at 100 ℃ for 4 hours. The mixture was filtered and the filtrate was concentrated to give the crude product. The crude product is purified by flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate 100/0 to 30/70). The eluent was collected and the solvent was concentrated under reduced pressure to give the product as a yellow solid (0.6g, 60% yield).¹H NMR (400MHz, chloroform-d) δ ppm 1.28-1.38(m,3H),1.53(s,9H),4.19-4.30(m,2H),4.39(br s,1H),7.15(br s,1H),7.24(s,1H),7.46(s,1H),7.47(d, J ═ 4.65Hz,1H),7.72(s, 1H). LC-MS (ES, M/z) [ M +1 ]]⁺336.2

C.5-amino-1- (6-amino-5-fluoropyridin-2-yl) -1H-pyrazole-4-carboxylic acid ethyl ester, Compound 8c

A solution of ethyl 5-amino-1- (6- ((tert-butoxycarbonyl) amino) -5-fluoropyridin-2-yl) -1H-pyrazole-4-carboxylate (600mg, 1.43mmol) and HCl in MeOH (15mL) was stirred at 30 ℃ for 1H. The mixture was concentrated to dryness to give the title product as an orange gum (450mg, 86.4%) which was used in the next step without purification. LC-MS (ES) is a linear mass spectrometer,m/z):[M+1]⁺266.1

5-amino-1- (8-fluoroimidazo [1,2-a ]]Pyridin-5-yl) -1H-pyrazole-4-carboxylic acid ethyl ester, Compound 8d

In N₂Next, ethyl 5-amino-1- (6-amino-5-fluoropyridin-2-yl) -1H-pyrazole-4-carboxylate (450mg, 1.70mmol) was dissolved in ethanol (10 mL). To the suspension was added 2-bromo-1, 1-diethoxyethane (668.7mg, 3.39mmol), followed by HBr (1 mL). The resulting mixture was then refluxed for 18 hours and cooled to room temperature. The solvent was removed under reduced pressure. To the mixture was added 10% NaHCO₃Aqueous (10mL) and the mixture extracted with EtOAc (50 mL. times.2). The combined organic layers were concentrated to dryness under reduced pressure to give the crude title product. The crude product is purified by chromatography on silica gel (eluent: petroleum ether/ethyl acetate 100/0 to 50/50). The purified fractions were collected and the solvent was concentrated under reduced pressure to give the product as a pale green solid (190mg, 38.7% yield). LC-MS (ES, M/z) [ M +1 ]]⁺290.1

E.1- (8-Fluoroimidazo [1, 2-a)]Pyridin-5-yl) -5- (methylthio) -1H-pyrazole-4-carboxylic acid ethyl ester, compound 8e

At 0 ℃ in N₂Next, isoamyl nitrite (178.2mg, 1.52mmol) was added dropwise to 5-amino-1- (8-fluoroimidazo [1,2-a ]]Pyridin-5-yl) -1H-pyrazole-4-carboxylic acid ethyl ester (220mg, 0.76mmol) and 1, 2-dimethyldisulfane (143.3mg, 1.52mmol) in chloroform (10 mL). The reaction mixture was stirred at room temperature for 36 hours. Water (40mL) was then added to the mixture, and the mixture was extracted with dichloromethane (50 mL. times.3). The combined organic layers were dried over MgSO₄Dried and concentrated under reduced pressure to give the crude product. The crude product is chromatographed on silica gel (eluent: petroleum ether)Ethyl acetate 100:0 to 50:50) to give the title compound as a yellow oil (160mg, 60.8% yield). LC-MS (ES, M/z) [ M +1 ]]⁺321.2

F.1- (8-Fluoroimidazo [1, 2-a)]Pyridin-5-yl) -5- (methylsulfonyl) -1H-pyrazole-4-carboxylic acid ethyl ester, Compound Object 8f

To 1- (8-fluoroimidazo [1,2-a ]]To a solution of pyridin-5-yl) -5- (methylthio) -1H-pyrazole-4-carboxylic acid ethyl ester (220mg, 0.64mmol) in dichloromethane (20mL) was added m-CPBA (331mg, 1.92 mmol). The mixture was stirred at room temperature overnight. The reaction mixture was washed with saturated aqueous sodium bisulfite (20mL × 3) to destroy excess oxidizing agent. The mixture was then washed twice with saturated aqueous sodium bicarbonate (20mL) and brine (30 mL). The combined organic layers were dried over MgSO₄Dried and concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel column chromatography (petroleum ether/ethyl acetate 100:0 to 50:50) to give the title compound as a yellow solid (80mg, 35.6% yield).¹H NMR(400MHz,DMSO-d6)δppm 1.29(t,J＝7.09Hz,3H),3.59(s,3H),4.30(q,J＝7.09Hz,2H),7.43-7.57(m,1H),8.03(t,J＝9.05Hz,1H),8.27(s,1H),8.85-9.25(m,1H),11.06(br s,1H)。LC-MS:(ES,m/z):[M+1]⁺353.1

G.1- (8-Fluoroimidazo [1,2-a ]]Pyridin-5-yl) -5- (methylsulfonyl) -1H-pyrazole-4-carboxylic acid, Compound 8g

To 1- (8-fluoroimidazo [1,2-a ]]To a solution of pyridin-5-yl) -5- (methylsulfonyl) -1H-pyrazole-4-carboxylic acid ethyl ester (80mg, 0.23mmol) in THF (8mL) and water (2mL) was added lithium hydroxide (95.3mg, 2.27 mmol). The reaction mixture was stirred at room temperature overnight. EtOAc (20mL) is added to the mixture and purified by addition of 3M HClThe mixture was adjusted to pH 1. The mixture was then extracted with EtOAc (30 mL. times.3). The organic layer was purified over MgSO₄Drying, filtration and concentration of the filtrate gave the product as a white solid (60mg, 81.5% yield). LC-MS (ES, M/z) [ M +1 ]]⁺325.1

H.N- (5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a ]]Pyridine- 5-yl) -5- (methylsulfonyl) -1H-pyrazole-4-carboxamide, Compound 8

Adding POCl₃(113.5mg, 0.74mmol) was added dropwise to 1- (8-fluoroimidazo [1, 2-a)]Pyridin-5-yl) -5- (methylsulfonyl) -1H-pyrazole-4-carboxylic acid (60mg, 0.19mmol), 5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-amine (43.4mg, 0.22mmol), and pyridine (87.8mg, 1.11mmol) in dichloromethane (10 mL). The mixture was stirred at room temperature for 2 hours. By addition of saturated NaHCO₃The solution adjusts the mixture to pH 9-10. Water (30mL) was added and the mixture was extracted with dichloromethane (30 mL. times.3). The combined organic layers were dried over MgSO₄Drying, filtering and concentrating the filtrate under reduced pressure to obtain the crude product. The product was purified by preparative high performance liquid column chromatography: boston Prime C18150 × 30mm 5 um. Conditions are as follows: a: water (0.05% ammonium hydroxide v/v); b: CH (CH)₃CN; at the beginning: a (69%) and B (31%), end: a (39%) and B (61%). Gradient time (min) 8; 100% B hold time (min) 2; flow rate (ml/min) 25. The purified fractions were collected and the organic solvent was concentrated under reduced pressure and then lyophilized to dryness to give the product as a white solid (13.0mg, 13.9% yield).¹H NMR(400MHz,DMSO-d6)δppm 3.59(s,3H),7.35-7.44(m,2H),7.51(dd,J＝8.07,3.91Hz,1H),7.71(d,J＝0.98Hz,1H),8.17(s,2H),8.61-8.69(m,2H),8.81(d,J＝2.20Hz,1H)。LC-MS:(ES,m/z):[M+1]⁺502.1

Example 9

N- (5-chloro-6- (5-methyloxazol-2-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, compound 9

A.5-bromo-3-chloro-N- (prop-2-yn-1-yl) picolinamide, compound 9a

A mixture of 5-bromo-3-chloropicolinic acid (500mg, 2.12mmol), HOBT (143mg, 2.54mmol), DECI (405mg, 1.06mmol), and TEA (428mg, 4.23mmol) in DMF (5mL) was stirred at room temperature for 0.5 h. Prop-2-yn-1-amine (140mg, 2.54mmol) was added to the mixture. The mixture was stirred at room temperature for 12 hours. To the mixture was added water (10mL), and the mixture was extracted with EtOAc (20 mL. times.3). The combined organic layers were passed over Na₂SO₄Drying, filtration and concentration of the filtrate gave the crude product. The crude product is purified by flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate 100/0 to 100/50). The eluent was collected and the solvent was concentrated under reduced pressure to give the title compound (160mg, 27.7% yield). LC-MS (ES, M/z) [ M +1 ]]⁺274.9

B.2- (5-bromo-3-chloropyridin-2-yl) -5-methyloxazole, Compound 9b

Trifluoromethanesulfonic acid (878mg, 5.85mmol) was added dropwise to a solution of 5-bromo-3-chloro-N- (prop-2-yn-1-yl) picolinamide (160mg, 0.59mmol) in dichloromethane (3mL) and the mixture was stirred at 90 ℃ for 14 h. To the mixture was added water (5mL), and the mixture was extracted with EtOAc (10 mL. times.3). The combined organic layers were passed over Na₂SO₄Dried and concentrated to give the crude product. The crude product is purified by flash column chromatography on silica gel (eluent: petroleum)Ether/ethyl acetate 100/0 to 0/100). The eluent was collected and the solvent was concentrated under reduced pressure to give the product as a white solid (110mg, 68.8% yield).¹H NMR(400MHz,DMSO-d6)δppm 2.41(d,J＝1.2Hz,3H),7.16(d,J＝1.0Hz,1H),8.53(d,J＝2.0Hz,1H),8.80(d,J＝2.0Hz,1H)。LC-MS:(ES,m/z):[M+1]⁺274.9

C.3, 6-difluoro-2-hydrazinopyridines, Compound 9c

To an ice-cold solution of 2,3, 6-trifluoropyridine (4g, 30.06mmol) in EtOH (50mL) was added hydrazine hydrate (3.071g, 60.12 mmol). The reaction mixture was warmed to room temperature and then heated to reflux for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (50mL) and CH₂Cl₂(2X 100 mL). The combined organic layers were passed over anhydrous Na₂SO₄Dried, filtered and the filtrate concentrated under reduced pressure. The residue was recrystallized from EtOH to obtain the product as a pale yellow solid (3g, yield: 68.8%).

2-bromo-3, 6-difluoropyridine, compound 9d

Br at room temperature₂(2.13mL, 41.35mmol) was added dropwise to a stirred solution of 3, 6-difluoro-2-hydrazinopyridine (3g, 20.67mmol) in CHCl₃(45mL) in solution. The mixture was stirred at 60 ℃ for 1 hour. The mixture was cooled to 0 ℃ and saturated NaHCO was added dropwise₃Solution (200 mL). Adding CH₂Cl₂(200mL), the organic layer was separated and dried (Na)₂SO₄) The solvent was filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (petroleum ether: EtOAc ═ 1:0 to 9:1) to give the product as a yellow oil (1.7g, yield: 42.4%).¹H NMR(400MHz,DMSO-d6)δppm 6.92(td,J＝3.1,8.7Hz,1H),7.55(td,J＝6.2,8.6Hz,1H)。

E.2-bromo-3-fluoro-6-hydrazinopyridin, Compound 9e

2-bromo-3, 6-difluoropyridine (2.7g, 13.92mmol) was dissolved in MeCN (50mL) and hydrazine hydrate (1.422g, 27.84mmol) was added. The reaction mixture was stirred at 80 ℃ for 16 hours. The reaction mixture was concentrated under reduced pressure to give the crude product as a yellow solid (2.868g, yield: 100%).

F.1- (6-bromo-5-fluoropyridin-2-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid ethyl ester, Compound 9f

2-bromo-3-fluoro-6-hydrazinopyridine (2.8g, 13.59mmol) was dissolved in EtOH (60mL), ethyl 2- (ethoxymethylene) -4,4, 4-trifluoro-3-oxobutanoate (6.529g, 27.18mmol) was added and stirred at 60 ℃ for 2 hours. The mixture was concentrated under reduced pressure to give the crude product. The crude product is purified by flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate 100/0 to 80/20). The desired fractions were collected, and the solvent was concentrated under reduced pressure to give a yellow solid compound (2g, yield: 38.5%).¹H NMR(400MHz,DMSO-d6)δppm 1.38-1.41(m,3H),4.37-4.41(m,2H),7.63-7.67(m,2H),8.11(s,1H)。

G.1- (6- ((tert-butoxycarbonyl) amino) -5-fluoropyridin-2-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid Ethyl acid ester, Compound 9g

Pd (OAc)₂(58.755mg, 0.26mmol) and Xantphos (151.428mg, 0.26mmol)The dioxane (50mL) solution was stirred at room temperature under nitrogen for 10 minutes. Then ethyl 1- (6-bromo-5-fluoropyridin-2-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylate (2g, 5.23mmol), Cs were added at room temperature₂CO₃(5.116g, 15.70mmol) and tert-butyl carbamate (0.736g, 6.28 mmol). The reaction mixture was then heated at 90 ℃ overnight and then cooled to room temperature. The reaction mixture was filtered through a pad of celite. The filtrate was concentrated under reduced pressure and then purified by flash column chromatography on silica gel (eluent: petroleum ether/EtOAc 100/0 to petroleum ether/EtOAc 80/20). The desired fractions were collected, and the solvent was concentrated to dryness under reduced pressure to give the desired product as a yellow solid (1800mg, yield: 82.2%).

H.1- (6-amino-5-fluoropyridin-2-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid ethyl ester, Compound 9H

Ethyl 1- (6- ((tert-butoxycarbonyl) amino) -5-fluoropyridin-2-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylate (0.9g, 2.15mmol) and HCl/MeOH (18mL, 4M) were stirred at 30 ℃ for 1H. The mixture was concentrated to dryness. To the residue was added saturated K₂CO₃Aqueous solution (50 mL). The mixture was extracted with EtOAc (50 mL. times.3). The combined organic layers were passed over Na₂SO₄Drying, filtration and concentration of the filtrate to dryness gave the product as an orange gum (650mg, yield: 94.9%).

1- (8-Fluoroimidazo [1,2-a ]]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid ethyl ester, Compound (I) Thing 9i

In N₂Next, ethyl 1- (6-amino-5-fluoropyridin-2-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylate (650mg, 2.043mmol) was dissolved in EtOH (20 mL). Adding to the suspension2-bromo-1, 1-diethoxyethane (805.057mg, 4.085mmol) was added, followed by HBr (2mL, 48% aq). The resulting mixture was then refluxed for 12 hours and cooled to room temperature. The solvent was removed under reduced pressure. The residue was purified by silica gel flash column chromatography (petroleum ether: ethyl acetate: 10:1 to 1: 1). The purified fractions were collected, and the solvent was concentrated under reduced pressure to give the product as a pale yellow solid (320mg, yield: 45.8%).¹H NMR(400MHz,CHLOROFORM-d)δppm 1.40(t,J＝7.2Hz,3H),4.42(q,J＝7.1Hz,2H),6.91(dd,J＝4.0,7.9Hz,1H),7.04(dd,J＝8.0,9.4Hz,1H),7.12(s,1H),7.70(s,1H),8.30(s,1H)。

J.1- (8-fluoroimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid, Compound 9j

A mixture of ethyl 1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylate (320mg, 0.935mmol) in concentrated HCl (6.064mL) was stirred at 130 ℃ for 2 hours. The solvent was concentrated under reduced pressure to give the product as a yellow solid (300mg, crude).

K.N- (5-chloro-6- (5-methyloxazol-2-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1, 2-a)]Pyridine-5- 5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 9

Pd is added₂(dba)₃(44mg, 0.048mmol) and 4, 5-bis (diphenylphosphino) -9, 9-dimethylxanthene (140mg, 0.24mmol) were added to 1- (8-fluoroimidazo [1,2-a ]]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide (50mg, 0.16mmol), 2- (5-bromo-3-chloropyridin-2-yl) -5-methyloxazole (52mg, 0.19mmol) and cesium carbonate (33mg, 0.24mmol) in toluene (3 mL). Mixing the mixture in N₂The mixture was stirred at 80 ℃ for 14 hours. To the mixture was added water (5mL) and the mixture was washed with waterThe mixture was extracted with EtOAc (10 mL. times.3). The combined organic layers were passed over Na₂SO₄Drying, filtration and concentration of the filtrate gave the crude product. The crude product was purified by preparative high performance liquid chromatography. Column: xtate C1810 μ 250mm x 50mm, conditions: a: water (0.04% NH)₃H₂O+10mM NH₄HCO₃) (ii) a B: MeCN, start with: a (60%) and B (40%), end: a (30%) and B (70%). Gradient time (min) 8; 100% B hold time (min) 2; flow rate (ml/min) 25. The purified fractions were collected, and the solvent was concentrated under reduced pressure, followed by lyophilization to dryness to give the title compound (33mg, 40.7%).¹H NMR(400MHz,DMSO-d₆)δppm 2.42(d,J＝1.2Hz,3H),7.14(d,J＝1.2Hz,1H),7.41-7.55(m,3H),7.79(d,J＝1.2Hz,1H),8.55(d,J＝2.2Hz,1H),8.70(s,1H),8.92(d,J＝2.2Hz,1H),11.20(br s,1H)。LC-MS:(ES,m/z):[M+1]⁺506.1

Example 10

N- (5-chloro-6- (4-methyloxazol-2-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, compound 10

A.5-bromo-3-chloropyridoformyl chloride, Compound 10a

A solution of oxalyl chloride (3.60mL, 42.3mmol) in DMF (0.05mL) was added to a solution of 5-bromo-3-chloropicolinic acid (5.0g, 22.15mmol) in dichloromethane at 0 ℃. The mixture was stirred at room temperature for 2 hours. The solvent was concentrated under reduced pressure to give the crude product (5.5g, 100% yield).

(S) -5-bromo-3-chloro-N- (1- (methoxy (methyl) amino) -1-oxopropan-2-yl) picolinamide, combined Object 10b

5-bromo-3-chloropyridoformyl chloride (200mg, 0.79mmol) was added to a solution of (S) -2-amino-N-methoxy-N-methylpropanamide (132mg, 0.79mmol) and TEA (397mg, 3.92mmol) in dichloromethane (20 mL). The mixture was stirred at room temperature for 16 hours. Brine (30mL) was added to the mixture and the mixture was extracted with EtOAc (50 mL. times.2). The combined organic layers were concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 1:0 to petroleum ether/ethyl acetate 1: 1). The desired fractions were collected and the solvent was concentrated under reduced pressure to give the product as a yellow solid (180mg, 65.43% yield).¹H NMR(400MHz,DMSO-d6)δppm 1.28(3H,d,J＝7.09Hz),3.13(3H,s),3.77(3H,s),4.89(1H,br t,J＝6.97Hz),8.43(1H,d,J＝1.71Hz),8.70(1H,d,J＝1.96zH),8.84(1H,br d,J＝7.58Hz)。LC-MS:(ES,m/z):[M+1]⁺352.0

(S) -5-bromo-3-chloro-N- (1-oxopropan-2-yl) picolinamide, Compound 10c

(S) -5-bromo-3-chloro-N- (1- (methoxy (methyl) amino) -1-oxopropan-2-yl) picolinamide (2.0g, 5.71mmol) was dissolved in THF (30mL) and the mixture was stirred at-78 deg.C for 10 min. A solution of lithium aluminum hydride (238.2mg, 6.28mmoL) in THF (30mL) was slowly added to the mixture. The reaction was stirred at 0 ℃ for 1 hour. Water (0.24mL) was added slowly followed by 10% NaOH solution (0.24mL) and additional water (0.72 mL). The mixture was stirred at room temperature for 1 min, filtered and the organic phase was concentrated under reduced pressure to give a yellow oil which was then purified by silica gel column chromatography (eluent: petroleum ether to petroleum ether/ethyl acetate ═ 1: 1). The desired fractions were collected and the solvent was concentrated under reduced pressure to give the product as a yellow oil (1.8g, 50.8% yield). LC-MS (ES, M/z) [ M +1 ]]⁺293.0

2- (5-bromo-3-chloropyridin-2-yl) -4-methyloxazole, Compound 10d

(S) -5-bromo-3-chloro-N- (1-oxopropan-2-yl) picolinamide (1.7g, 2.74mmol) was dissolved in methanesulfonic acid (30mL) and phosphorus (V) oxide (1.17g, 8.21mmol) was added. The reaction mixture was stirred at 140 ℃ for 1 hour. The reaction mixture was slowly poured into water (200mL) and the mixture was extracted with EtOAc (200mL × 3). The combined organic layers were passed over Na₂SO₄Drying, filtration and concentration of the filtrate under reduced pressure gave the crude product as a black solid. The crude product is purified by flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate 100/0 to 50/50). The desired fractions were collected and the solvent was concentrated under reduced pressure to give the title compound as a white solid (110mg, 14.1% yield). LC-MS (ES, M/z) [ M +1 ]]⁺275.0

E.N- (5-chloro-6- (4-methyloxazol-2-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1, 2-a)]Pyridine-5- 5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 10

Pd is added₂(dba)₃(22mg, 0.024mmol) and 4, 5-bis (diphenylphosphino) -9, 9-dimethylxanthene (46.5mg, 0.080mmol) were added to 1- (8-fluoroimidazo [1,2-a ]]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide (138mg, 0.44mmol), 2- (5-bromo-3-chloropyridin-2-yl) -4-methyloxazole (110mg, 0.40mmol) and cesium carbonate (197mg, 0.60mmol) in toluene (5 mL). Mixing the mixture in N₂The mixture was stirred at 80 ℃ for 14 hours. To the mixture was added water (5mL) and the mixture was extracted with EtOAc (10 mL. times.3). The combined organic layers were passed over Na₂SO₄Drying, filtering and concentrating the filtrate,the crude product is obtained. The crude product was purified by preparative high performance liquid chromatography. Column: xtate C1810 μ 250mm x 50mm, conditions: a: water (0.04% NH)₃H₂O+10mM NH₄HCO₃) (ii) a B: MeCN, start with: a (60%) and B (40%), end: a (30%) and B (70%). Gradient time (min) 8.5; 100% B hold time (min) 2; the flow rate (ml/min) was 30. The purified fractions were collected, the solvent was concentrated under reduced pressure, and lyophilized to dryness to give the title compound as a pale yellow solid (60mg, 29.2%).¹H NMR(400MHz,DMSO-d6)δppm 2.18(3H,s),7.39-7.43(1H,m),7.44-7.48(1H,m),7.50(1H,d,J＝2.93Hz),7.75(1H,s),8.00(1H,s),8.51(1H,d,J＝1.96Hz),8.66(1H,s),8.90(1H,d,J＝1.96Hz),11.17(1H,br s)。LC-MS:(ES,m/z):[M+1]⁺506.0

Example 11

1- (7-cyanopyrazolo [1,5-a ] pyridin-4-yl) -5- (trifluoromethyl) -N- (2- (trifluoromethyl) pyridin-4-yl) -1H-pyrazole-4-carboxamide, Compound 11

A.4-hydrazinopyrazolo [1,5-a ]]Pyridine-7-carbonitrile, Compound 11a

Hydrazine (812mg, 25.3mmol) was added to a solution of 4-chloropyrazolo [1,5-a ] pyridine-7-carbonitrile (150mg, 0.85mmol) in acetonitrile (7.5 mL). The mixture was stirred at 90 ℃ for 6 hours. EtOH (30 mL. times.2) was added to the mixture. The solvent was concentrated under reduced pressure to give the crude product as a yellow oil (160mg), which was used directly in the next step.

B.1- (7-cyanopyrazolo [1,5-a ]]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid ethyl ester and esterification Compound 11b

Ethyl 2- (ethoxymethylene) -4,4, 4-trifluoro-3-oxobutanoate (222mg, 0.92mmol) was added to 4-hydrazinylpyrazolo [1,5-a ]]Pyridine-7-carbonitrile (160mg, 0.92mmol) in ethanol (10 mL). The mixture was stirred at 80 ℃ for 2 hours. The solvent was concentrated under reduced pressure to give the crude product as a brown oil. The crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 1:0 to petroleum ether/ethyl acetate 2: 1). The desired fractions were collected and the solvent was concentrated under reduced pressure to give the product as a yellow solid (320 mg). LC-MS (ES, M/z) [ M +1 ]]⁺350.0

C.1- (7-cyanopyrazolo [1,5-a ]]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid, compounds 11c

Lithium hydroxide (30.9mg, 1.29mmol) was added to 1- (7-cyanopyrazolo [1,5-a ]]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid ethyl ester (300mg, 0.86mmol) in THF/water (1:1, 2.5 mL). The mixture was reacted at room temperature for 3 hours. The solvent was removed under reduced pressure, and water (20mL) was added to the mixture. The mixture was adjusted to pH 5 by addition of 1M hydrochloric acid, and then extracted with ethyl acetate (30mL × 3). The combined organic layers were washed with brine, over MgSO₄Drying, filtering, and concentrating the filtrate under reduced pressure to obtain 1- (7-cyanopyrazolo [1,5-a ]]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid and 1- (7-carbamoylpyrazolo [1,5-a ]]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid. The mixture was then treated with pyridine (80.8mg, 1.02mmol) and 2,2, 2-trifluoroacetic anhydride (103mg, 0.49mmol) in THF (5mL) for 1h at room temperature. The mixture was adjusted to pH 5 by addition of 1M hydrochloric acid, and then extracted with ethyl acetate (30mL × 3). The combined organic layers were washed with brine, over MgSO₄Drying, filtering, and reducing the filtrateConcentration under pressure gave the product as a yellow solid (300mg), which was used directly in the next step. LC-MS (ES, M/z) [ M +1 ]]⁺322.0

1- (7-Cyanopyrazolo [1,5-a ]]Pyridin-4-yl) -5- (trifluoromethyl) -N- (2- (trifluoromethyl) pyridine- 4-yl) -1H-pyrazole-4-carboxamide, Compound 11

Adding POCl₃(0.13mL, 1.68mmol) was added to 1- (7-cyanopyrazolo [1,5-a ]]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid (300mg, 0.69mmol), 2- (trifluoromethyl) pyridin-4-amine (111.6mg, 0.69mmol) and pyridine (0.28mL, 3.44mmol) in a mixture of methylene chloride (10 mL). The reaction mixture was stirred at 20 ℃ for 1 hour. Saturated NaHCO₃Aqueous solution (20mL) was added to the mixture. Subjecting the mixture to CH₂Cl₂(30 mL. times.2). The combined organic layers were washed with brine, over Na₂SO₄Drying, filtration and concentration of the filtrate under reduced pressure gave the crude product as a brown oil. The crude product was purified by preparative high performance liquid chromatography: column: phenomenex Gemini 150 × 25mm × 10 um; conditions are as follows: a: water (0.05% ammonium hydroxide v/v); b: MeCN, start with: a (50%) and B (50%); and (4) at the end: a (20%) and B (80%). Gradient time (min) 10; 100% B hold time (min) 2.2; flow rate (ml/min) 25. The purified fractions were collected, the organic solvent was concentrated under reduced pressure, and the residue was lyophilized to dryness to give the product (172mg, 52.2%) as a yellow solid.¹H NMR(400MHz,DMSO-d6)δppm 6.69(1H,d,J＝2.51Hz),7.79(1H,d,J＝7.78Hz),7.98(1H,dd,J＝5.52,1.76Hz),8.06(1H,d,J＝7.78Hz),8.24(1H,d,J＝1.76Hz),8.36(1H,d,J＝2.26Hz),8.63(1H,s),8.72(1H,d,J＝5.52Hz),11.28(1H,br s)。LC-MS:(ES,m/z):[M+1]⁺465.9

Example 12

4- (5- (trifluoromethyl) -4- ((2- (trifluoromethyl) pyridin-4-yl) carbamoyl) -1H-pyrazol-1-yl) pyrazolo [1,5-a ] pyridine-7-carboxamide, compound 12

A.1- (7-carbamoylpyrazolo [1,5-a ]]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid, compound 12a

Lithium hydroxide (60.0mg, 2.50mmol) was added to 1- (7-cyanopyrazolo [1,5-a ]]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid ethyl ester (500mg, 1.25mmol) in THF/water (92:1, 6 mL). The mixture was reacted at room temperature for 16 hours. To the mixture was added water (20 mL). The mixture was adjusted to pH 5 by addition of 1M hydrochloric acid, and then extracted with ethyl acetate (30mL × 3). The combined organic layers were washed with brine, over MgSO₄Drying, filtration, and concentration of the filtrate under reduced pressure gave a brown oil which was purified by preparative high performance liquid chromatography: column: agela ASB 150 × 25mm × 5 um. Conditions are as follows: a: water (0.05% HCl), B: MeCN, start with: a (75%) and B (25%), end: a (45%) and B (55%). Gradient time (min) 8; 100% B hold time (min) 0; flow rate (ml/min) 25. The purified fractions were collected, the organic solvent was concentrated under reduced pressure and the resulting residue was lyophilized to dryness to give the product as a white solid (170mg, 40.2% yield). LC-MS (ES, M/z) [ M +1 ]]⁺339.9

4- (5- (trifluoromethyl) -4- ((2- (trifluoromethyl) pyridin-4-yl) carbamoyl) -1H-pyrazol-1-yl) Pyrazolo [1,5-a]Pyridine-7-carboxamides, Compound 12

Adding POCl₃(0.13mL, 1.68mmol) was added to 1- (7-carbamoylpyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid (80mg, 0.23mmol), 2- (trifluoromethyl) pyridin-4-amine (38.2mg, 0.23mmol) and pyridine (38.3mg, 0.47mmol) in a mixture of methylene chloride (6 mL). The reaction mixture was stirred at 20 ℃ for 1 hour. NaHCO is added₃(solution) (20mL) was added to the mixture. Subjecting the mixture to CH₂Cl₂(30 mL. times.2). The combined organic layers were washed with brine, over Na₂SO₄Drying, filtration and concentration of the filtrate under reduced pressure gave the crude product as a brown oil. The crude product was purified by preparative high performance liquid chromatography: column: phenomenex Gemini 150 × 25mm × 10 um; conditions are as follows: a: water (0.05% ammonium hydroxide v/v); b: MeCN, start with: a (85%) and B (15%); and (4) at the end: a (55%) and B (45%). Gradient time (min) 12; 100% B hold time (min) 2.2; flow rate (ml/min) 25. The purified fractions were collected, concentrated under reduced pressure and lyophilized to dryness to give the product (44mg, 38.6%) as a pale yellow solid.¹H NMR(400MHz,DMSO-d6)δppm 6.57(1H,d,J＝2.45Hz),7.71-7.76(1H,m),7.78-7.83(1H,m),7.96(1H,dd,J＝5.38,1.71Hz),8.22(1H,d,J＝1.71Hz),8.31(1H,d,J＝2.45Hz),8.55(1H,br s),8.58(1H,s),8.70(1H,d,J＝5.38Hz),9.48(1H,br s),11.27(1H,br s)。LC-MS:(ES,m/z):[M+1]⁺483.9

As those skilled in the art will readily recognize, following the procedure described in example 12 above, the appropriate reagents, starting materials and purification methods were selected and replaced, and the reaction temperature, reaction time and other variables or parameters were adjusted as needed or desired, to prepare the following compounds (13-16).

Example 13

N- (5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (7-cyanopyrazolo [1,5-a ] pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 13

¹H NMR(400MHz,DMSO-d6)δppm 6.67(1H,d,J＝2.45Hz),7.76(1H,d,J＝7.58Hz),8.03(1H,d,J＝7.83Hz),8.16(2H,s),8.33(1H,d,J＝2.20Hz),8.56-8.67(2H,m),8.81(1H,d,J＝2.20Hz),11.20(1H,br s)。LC-MS:(ES,m/z):[M+1]⁺499.0

Example 14

1- (7-chloropyrazolo [1,5-a ] pyridin-4-yl) -5- (trifluoromethyl) -N- (2- (trifluoromethyl) pyridin-4-yl) -1H-pyrazole-4-carboxamide, compound 14

¹H NMR(400MHz,DMSO-d6)δppm 6.53(d,J＝2.20Hz,1H),7.43(d,J＝7.83Hz,1H),7.65(d,J＝7.83Hz,1H),7.94(dd,J＝5.62,1.71Hz,1H),8.20(d,J＝1.96Hz,1H),8.26(d,J＝2.20Hz,1H),8.54(s,1H),8.68(d,J＝5.38Hz,1H),11.24(br s,1H)。LC-MS:(ES,m/z):[M+1]⁺475.1

Example 15

N- (5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (7-chloropyrazolo [1,5-a ] pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 15

¹H NMR(400MHz,DMSO-d6)δppm 6.54(d,J＝2.20Hz,1H),7.43(d,J＝8.07Hz,1H),7.66(d,J＝7.83Hz,1H),8.16(s,2H),8.26(d,J＝2.20Hz,1H),8.56(s,1H),8.64(d,J＝2.20Hz,1H),8.81(d,J＝2.45Hz,1H)。LC-MS:(ES,m/z):[M+1]⁺508.1

Example 16

4- (4- ((5-chloro-6- (2H-1,2, 3-triazol-2-yl) pyridin-3-yl) carbamoyl) -5- (trifluoromethyl) -1H-pyrazol-1-yl) pyrazolo [1,5-a ] pyridine-7-carboxamide, compound 16

¹H NMR(400MHz,DMSO-d6)δppm 6.58(1H,d,J＝2.45Hz),7.71-7.77(1H,m),7.78-7.85(1H,m),8.18(2H,s),8.31(1H,d,J＝2.45Hz),8.56(1H,br s),8.60(1H,s),8.66(1H,d,J＝1.96Hz),8.84(1H,d,J＝2.20Hz),9.49(1H,br s),11.27(1H,br s)。LC-MS:(ES,m/z):[M+1]⁺517.1

Example 17

(^*S) -N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (8-fluoroimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 17

A.5-bromo-3-chloro-2- (1-methoxyethyl) pyridine, compound 17a

To a mixture of 1- (5-bromo-3-chloropyridin-2-yl) ethan-1-ol (8.7g, 36.8mmol) in DMF (8ml) at 0 ℃ was added NaH (60%, 2.65g, 66.2 mmol). The reaction mixture was stirred at room temperature for 30 minutes, then CH was added dropwise at 0 deg.C₃I (26.8g, 188.8 mmol). The mixture was stirred at room temperature for 2 hours. Addition of saturated NH₄Aqueous Cl (50mL) and the mixture extracted with EtOAc (150 mL. times.2). The combined organic layers were passed over Na₂SO₄Dried, filtered and the filtrate concentrated under reduced pressure. The crude product is purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate gradient 100/0 to 85/15). The desired fractions were collected and the solvent was concentrated under reduced pressure to give the title compound (6.1g, 61%) as a yellow oil. LC/MS (ESI): c₈H₉The mass calculation value of BrClNO is 249, and the M/z found value is 250.0[ M + H ]]⁺

Tert-butyl (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) carbamate, Compound 17b

5-bromo-3-chloro-2- (1-methoxyethyl) pyridine (6.1g, 22.5mmol), tert-butyl carbamate (3.1g, 27mmol) and Cs₂CO₃(14.6g, 45mmol) in dioxane (130ml) was stirred and the mixture was taken up with N₂Purge 5 minutes. Addition of Pd (OAc)₂(505mg, 2.25mmol) and 4, 5-bis (diphenylphosphino) -9, 9-dimethylxanthene (1.3g, 2.25mmol), and the mixture was stirred with N₂Purge for 1 minute. The reaction mixture was stirred at 110 ℃ for 16 hours. The mixture was concentrated under reduced pressure. The crude product is purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate gradient 100/0 to 50/50). The purified fractions were collected and the organic solvent was concentrated under reduced pressure to give the title compound (3.65g, 44%) as a white solid. LC/MS (ESI): c₁₃H₁₉ClN₂O₃Calculated mass of 286.1, found M/z of 287.1[ M + H ]]⁺

C.5-chloro-6- (1-methoxyethyl) pyridin-3-amine, Compound 17c

A mixture of tert-butyl (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) carbamate (3.65g, 9.92mmol) in HCl 4M solution in dioxane (40mL) was stirred at room temperature for 3 hours. The solvent was concentrated under reduced pressure. The crude product is purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate ratio 100/0 to 25/75). The purified fractions were collected and the organic solvent was concentrated under reduced pressure to give the title compound (1.64g, 88.5%) as a white solid. LC/MS (ESI): c₈H₁₁ClN₂Calculated by mass of O is 186.1 and found at M/z of 187.1[ M + H ]]⁺

(. S) -5-chloro-6- (1-methoxyethyl) pyridin-3-amine, Compound 17c-1 and (. R) -5-chloro-6- (1-methyl) Oxyethyl) pyridin-3-amine, Compound 17c-2

5-chloro-6- (1-methoxyethyl) pyridin-3-amine mono HCl salt (1.64g, 7.35mmol) was isolated by supercritical fluid chromatography. Column: DAICEL CHIRALPAK IC (250mm × 30mm, 10um) mobile phase: a: supercritical CO₂；B:0.1％NH₄ETOH solution of OH; the ratio was A55% B45%, 70 mL/min. The purified fractions were collected and the solvent was concentrated under reduced pressure to give (xs) -5-chloro-6- (1-methoxyethyl) pyridin-3-amine, compound 17c-1(604mg, 44%), LC/ms (esi): c₈H₁₁ClN₂Calculated by mass of O is 186.1 and found at M/z of 187.1[ M + H ]]⁺(ii) a And (× R) -5-chloro-6- (1-methoxyethyl) pyridin-3-amine, compound 17c-2(554mg, 40%), LC/ms (esi): c₈H₁₁ClN₂Calculated by mass of O is 186.1 and found at M/z of 187.1[ M + H ]]⁺

^*(S) -N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a ]]Pyridine-5- 5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 17

1- (8-fluoroimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid (87mg, 0.28mmol), (. about.S) -5-chloro-6- (1-methoxyethyl) pyridin-3-amine (51.9mg, 0.28mmol), POCl₃(51.8. mu.L, 0.55mmol) was dissolved in dichloromethane (5mL) and pyridine (111. mu.L, 1.64mmol) was added. The mixture was stirred at 25 ℃ for 1 hour. Addition of saturated NaHCO₃(20mL) with CH₂Cl₂The mixture was extracted (50 mL. times.2).The combined organic layers were passed over Na₂SO₄Drying, filtration and concentration of the filtrate under reduced pressure gave the crude product as a brown oil which was purified by preparative high performance liquid chromatography: column: phenomenex Gemini 150 × 25mm × 10 um. Conditions are as follows: a: water (0.05% ammonium hydroxide v/v) -CAN; b: MeCN, start with: a (60%) and B (40%), end: a (30%) and B (70%). Gradient time (min) 8; 100% B hold time (min) 2; flow rate (ml/min) 25. The purified fractions were collected, the organic solvent was concentrated under reduced pressure and the residue was lyophilized to dryness to give the product as a white solid (44.5mg, 33.3% yield).¹H NMR(400MHz,DMSO-d6)δppm 1.42(d,J＝6.36Hz,3H),3.17(s,3H),4.83(q,J＝6.36Hz,1H),7.40-7.57(m,3H),7.78(d,J＝1.22Hz,1H),8.37(d,J＝2.20Hz,1H),8.66(s,1H),8.80(d,J＝2.20Hz,1H)。LC/MS(ESI)：C₂₀H₁₅ClF₄N₆O₂Calculated mass of 482.1; m/z found 483.1[ M + H]⁺

Example 18

(^*R) -N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (8-chloroimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 18

A.3-bis- (tert-butoxycarbonyl) amino-5-chloropyridine, compound 18a

A mixture of 3-chloro-5-aminopyridine (5g, 38.9mmol) and DMAP (237.5mg, 1.95mmol) in THF (50mL) was stirred at room temperature. Boc anhydride (21.2g, 97.2mmol) in THF was added dropwise. Stirring was continued for 16 hours. Then 1.7 equivalents of BOC anhydride were added. Stirring was continued for 16 hours. The reaction mixture was concentrated under reduced pressure. The residue was stirred in diisopropyl ether. Is filtered to removeThe precipitate was obtained and dried to give the title product (6.1g, 47.7%). LC/MS (ESI): c₁₅H₂₁ClN₂O₄Calculated mass of 328.1, found M/z of 329.2[ M + H ]]⁺

B.3-bis- (tert-butoxycarbonyl) -5-chloro-6- (tetrahydrofuran-2-yl) pyridine, Compound 18b

To a solution of 3-bis- (tert-butoxycarbonyl) amino-5-chloropyridine (1g, 3mmol) in DMSO (30mL) was added PTSA (392.8mg, 2.28mmol), and the mixture was stirred at room temperature for 15 minutes. THF (14.8mL, 182.5mmol), ammonium persulfate (3.47g, 15mmol) and (IR [ DF (CF)₃)PPY]₂(DTBPY))PF₆(341.2mg, 0.3mmol), the mixture was degassed for 10 minutes and sealed. The reaction mixture was stirred at room temperature for 3 hours under blue LED illumination. Water (50mL) was added to the reaction mixture, and the aqueous layer was extracted with EtOAc (50 mL. times.2). In Na₂SO₄The combined organic layers were dried and filtered. The filtrate was concentrated under reduced pressure. The crude product is purified by flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate ratio 100/0 to 86/14). The desired fractions were collected and the solvent was concentrated under reduced pressure to give the title product (1g, 83%) as a colorless oil. LC/MS (ESI): c₁₉H₂₇ClN₂O₅Calculated mass of 398.1, found M/z of 399.0[ M + H]⁺

C.5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-amine, Compound 18c

To a solution of intermediate 3-bis- (tert-butoxycarbonyl) -5-chloro-6- (tetrahydrofuran-2-yl) pyridine (3g, 7.5mmol) in DCM (10mL) at 0 deg.C was added TFA (10 mL). The reaction mixture was stirred at 20 ℃ for 2 hours. To mixNaHCO is added to the product₃Aqueous (300mL) and the aqueous layer extracted with DCM (200 mL. times.3). The combined organic layers were passed over Na₂SO₄Dried, filtered and the filtrate concentrated under reduced pressure. The crude product is purified by flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate gradient 100/0 to 25/75). The desired fractions were collected and the solvent was concentrated under reduced pressure to give the title compound (1g, 64.4%) as a white solid. LC/MS (ESI): c₉H₁₁ClN₂Calculated by mass of O198.1, found M/z 198.9[ M + H]⁺

(. about) -5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-amine, compound 18c-1 and (. about.S) -5-chloro-6- (tetrahydro-furan-2-yl) pyridine-3-amine Furan-2-yl) pyridin-3-amine, Compound 18c-2

5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-amine, 18c (1g, 4.84mmol) was purified by SFC. Column: DAICEL CHIRALCEL OJ-H (250 mm. times.30 mm, 5um) condition: a: 0.1% NH₄ETOH solution of OH; b: EtOH; at the beginning: a (70%) and B (30%); and (4) at the end: a (70%) and B (30%). Flow rate (50 mL/min). The desired fractions were collected and the solvent was concentrated under reduced pressure to give (× R) -5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-amine, compound 18c-1(450mg, 45.7%), LC/ms (esi): c₉H₁₁ClN₂Calculated by mass of O198.1, found M/z 198.8[ M + H]⁺(ii) a And (× S) -5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-amine, compound 18c-2(450mg, 45.7%), LC/ms (esi): c₉H₁₁ClN₂Calculated by mass of O198.1, found M/z 198.8[ M + H]⁺As a white solid.

^*(R) -N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (8-chloroimidazo [1,2-a ]]Pyridine- 5-Yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 18

To 1- (8-chloroimidazo [1,2-a ] at 20 deg.C]To a solution of pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid (100mg, 0.29mmol) and pyridine (115.7. mu.L, 1.44mmol) in DCM (4mL) was added POCl₃(54. mu.L, 0.58 mmol). The reaction mixture was stirred at 20 ℃ for 5 minutes. At this point, a solution of (× R) -5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-amine (58.65mg, 0.29mmol) in dichloromethane (2mL) was added. The reaction mixture was stirred at 20 ℃ for 1 hour. The reaction mixture was poured into saturated NaHCO₃In solution (20 mL). The reaction mixture was extracted with dichloromethane (50 mL. times.3). The combined organic layers were washed with brine, over Na₂SO₄Dried and filtered. The filtrate was concentrated under reduced pressure. The crude product was purified by preparative high performance liquid chromatography. Column: phenomenex Gemini 150X 25mm, 10 um; conditions are as follows: a: 0.05% NH₄CH of OH₃CN solution; b: CH (CH)₃CN; at the beginning: a (60%) and B (40%); and (4) at the end: a (30%) and B (70%); flow rate (25 mL/min). The purified fractions were collected, the organic solvent was concentrated under reduced pressure, and the residue was lyophilized to dryness to give the title compound (98.6mg, 66.8%) as a white solid.¹H NMR(400MHz,DMSO-d6)δppm 1.87-2.12(m,2H),2.14-2.26(m,2H),3.82(br d,J＝6.36Hz,1H),3.89-3.98(m,1H),5.26(br t,J＝6.72Hz,1H),7.49(br d,J＝7.58Hz,1H),7.54(s,1H),7.74(br d,J＝7.58Hz,1H),7.80(s,1H),8.35(br s,1H),8.68(s,1H),8.76(br s,1H),11.00(br s,1H)。LC/MS(ESI)：C₂₁H₁₅Cl₂F₃N₆O₂Calculated mass of (d) is 510.1; m/z found 511.1[ M + H]⁺

As one skilled in the art will readily recognize, following the procedures described in examples 17 and 18 above, the appropriate reagents, starting materials and purification methods were selected and replaced, and the reaction temperature, reaction time and other variables or parameters were adjusted as needed or desired, to prepare the following compounds (19-28).

Example 19

(^*R) -N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (8-fluoroimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 19

¹H NMR(400MHz,DMSO-d6)δppm 1.42(d,J＝6.36Hz,3H),3.17(s,3H),4.83(q,J＝6.19Hz,1H),7.39-7.57(m,3H),7.78(s,1H),8.37(s,1H),8.66(s,1H),8.80(s,1H),11.00(br s,1H)。LC/MS(ESI)：C₂₀H₁₅ClF₄N₆O₂Calculated mass of 482.1; m/z found 483.1[ M + H]⁺

Example 20

(^*S) -N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (8-chloroimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 20

¹H NMR(400MHz,DMSO-d6)δppm 1.92-2.11(m,2H),2.14-2.27(m,2H),3.78-3.85(m,1H),3.93(q,J＝7.11Hz,1H),5.26(t,J＝6.90Hz,1H),7.49(d,J＝7.78Hz,1H),7.54(d,J＝1.00Hz,1H),7.75(d,J＝7.78Hz,1H),7.80(d,J＝1.00Hz,1H),8.35(d,J＝2.01Hz,1H),8.68(s,1H),8.76(d,J＝2.26Hz,1H),11.00(br s,1H)。LC/MS(ESI)：C₂₁H₁₅Cl₂F₃N₆O₂Calculated mass of (d) is 510.1; m/z found 511.1[ M + H]⁺

Example 21

(^*S) -N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (7-chloropyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 21

¹H NMR(400MHz,DMSO-d6)δppm 1.87-1.97(m,1H),1.99-2.07(m,1H),2.12-2.22(m,2H),3.75-3.82(m,1H),3.89(q,J＝7.09Hz,1H),5.23(t,J＝6.85Hz,1H),6.53(d,J＝2.45Hz,1H),7.42(d,J＝7.83Hz,1H),7.63(d,J＝7.83Hz,1H),8.26(d,J＝2.20Hz,1H),8.31(d,J＝2.20Hz,1H),8.50(s,1H),8.72(d,J＝2.20Hz,1H),10.96(br s,1H)。LC/MS(ESI)：C₂₁H₁₅Cl₂F₃N₆O₂Calculated mass of (d) is 510.1; m/z found 511.1[ M + H]⁺

Example 22

(^*R) -N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (7-chloropyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 22

1H NMR(400MHz,DMSO-d6)δppm 1.87-1.96(m,1H),1.98-2.04(m,1H),2.11-2.21(m,2H),3.74-3.82(m,1H),3.89(q,J＝7.17Hz,1H),5.23(t,J＝6.85Hz,1H),6.53(d,J＝2.20Hz,1H),7.42(d,J＝7.83Hz,1H),7.63(d,J＝7.83Hz,1H),8.26(d,J＝2.20Hz,1H),8.31(d,J＝1.96Hz,1H),8.50(s,1H),8.72(d,J＝1.96Hz,1H),10.96(s,1H)。LC/MS(ESI)：C₂₁H₁₅Cl₂F₃N₆O₂Calculated mass of (d) is 510.1; m/z found 511.1[ M + H]⁺

Example 23

(^*S) -N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (7-cyanopyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 23

¹H NMR(400MHz,DMSO-d6)δppm 1.90-2.00(1H,m),2.02-2.11(1H,m),2.14-2.26(2H,m),3.77-3.86(1H,m),3.93(1H,q,J＝7.03Hz),5.27(1H,t,J＝6.90Hz),6.69(1H,d,J＝2.51Hz),7.77(1H,d,J＝7.53Hz),8.06(1H,d,J＝7.53Hz),8.35(2H,t,J＝2.51Hz),8.60(1H,s),8.76(1H,d,J＝2.26Hz),11.03(1H,br s)。LC/MS(ESI)：C₂₂H₁₅ClF₃N₇O₂The calculated mass value of (a) is 501.1; found M/z is 502.1[ M + H]⁺

Example 24

(^*R) -N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (7-cyanopyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 24

¹H NMR(400MHz,DMSO-d6)δppm 1.87-1.97(1H,m),1.98-2.09(1H,m),2.11-2.23(2H,m),3.74-3.83(1H,m),3.90(1H,q,J＝7.25Hz),5.23(1H,t,J＝6.97Hz),6.65(1H,d,J＝2.45Hz),7.73(1H,d,J＝7.58Hz),8.02(1H,d,J＝7.83Hz),8.31(2H,t,J＝2.81Hz),8.55(1H,s),8.72(1H,d,J＝2.20Hz),10.99(1H,br s)。LC/MS(ESI)：C₂₂H₁₅ClF₃N₇O₂The calculated mass value of (a) is 501.1; found M/z is 502.1[ M + H]⁺

Example 25

(^*S) -N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (7-cyanopyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 25

¹H NMR(400MHz,DMSO-d6)δppm 1.42(3H,d,J＝6.27Hz),3.17(3H,s),4.83(1H,q,J＝6.44Hz),6.69(1H,d,J＝2.26Hz),7.77(1H,d,J＝7.78Hz),8.06(1H,d,J＝7.53Hz),8.36(2H,d,J＝1.76Hz),8.59(1H,s),8.80(1H,d,J＝2.26Hz),11.03(1H,br s)。LC/MS(ESI)：C₂₁H₁₅ClF₃N₇O₂Calculated mass of 489.1; found M/z was 490.1[ M + H]⁺

Example 26

(. about R) -N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (7-cyanopyrazolo [1,5-a ] pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 26

¹H NMR(400MHz,DMSO-d6)δppm 1.39(3H,d,J＝6.36Hz),3.14(3H,s),4.79(1H,q,J＝6.52Hz),6.66(1H,d,J＝1.96Hz),7.74(1H,d,J＝7.83Hz),8.02(1H,d,J＝7.58Hz),8.32(2H,s)8.55(1H,s),8.77(1H,s),10.98(1H,br s)。LC/MS(ESI)：C₂₁H₁₅ClF₃N₇O₂Calculated mass of 489.1; found M/z was 490.1[ M + H]⁺

Example 27

(^*S) -N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (7-chloropyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 27

¹H NMR(400MHz,DMSO-d6)δppm 1.33-1.44(m,1H),1.38(d,J＝6.36Hz,2H),3.13(s,3H),4.79(q,J＝6.52Hz,1H),6.53(s,1H),7.42(d,J＝7.83Hz,1H),7.63(d,J＝7.83Hz,1H),8.26(s,1H),8.33(s,1H),8.51(s,1H),8.78(s,1H),11.01(br s,1H)。LC/MS(ESI)：C₂₀H₁₅Cl₂F₃N₆O₂Calculated mass of 498.1; m/z found 499.0[ M + H]⁺

Example 28

(^*R) -N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (7-chloropyrazolo [1, 5-a)]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 28

¹H NMR(400MHz,DMSO-d6)δppm 1.38(br d,J＝6.36Hz,3H),3.13(s,2H),3.11-3.17(m,1H),4.79(br d,J＝5.62Hz,1H),6.53(s,1H),7.42(d,J＝7.34Hz,1H),7.63(d,J＝8.07Hz,1H),8.26(s,1H),8.33(s,1H),8.52(s,1H),8.78(s,1H),11.01(br s,1H)。LC/MS(ESI)：C₂₀H₁₅Cl₂F₃N₆O₂Calculated mass of 498.1; m/z found 499.1[ M + H]⁺

Example 29

N- (6- ((dimethyl (oxo) - δ λ)⁶-Thioalkylene) amino) -5-methylpyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 29

3, 6-difluoro-2-hydrazinopyridine, Compound 29a

To an ice-cold solution of 2,3, 6-trifluoropyridine (4g, 30.06mmol) in EtOH (50mL) was added hydrazine hydrate (3.071g, 60.12 mmol). The reaction mixture was warmed to room temperature and then heated to reflux for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (50mL) and CH₂Cl₂(2X 100 mL). The combined organic layers were passed over anhydrous Na₂SO₄Dried, filtered and the filtrate concentrated under reduced pressure. The residue was recrystallized from EtOH to give the product asPale yellow solid (3g, yield: 68.8%).

B.2-bromo-3, 6-difluoropyridine, compound 29b

C.2-bromo-3-fluoro-6-hydrazinopyridine, Compound 29c

1- (6-bromo-5-fluoropyridin-2-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid ethyl ester, Compound 29d

2-bromo-3-fluoro-6-hydrazinopyridine (2.8g, 13.59mmol) was dissolved in EtOH (60mL) and 2- (ethoxypyridine) was addedAcylmethylene) -ethyl 4,4, 4-trifluoro-3-oxobutanoate (6.529g, 27.18mmol) and stirred at 60 ℃ for 2 h. The mixture was concentrated under reduced pressure to give the crude product. The crude product is purified by flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate 100/0 to 80/20). The desired fractions were collected, and the solvent was concentrated under reduced pressure to give a yellow solid compound (2g, yield: 38.5%).¹H NMR(400MHz,DMSO-d6)δppm 1.38-1.41(m,3H),4.37-4.41(m,2H),7.63-7.67(m,2H),8.11(s,1H)。

E.1- (6- ((tert-butoxycarbonyl) amino) -5-fluoropyridin-2-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid Ethyl acid ester, Compound 29e

Pd (OAc)₂A solution of (58.755mg, 0.26mmol) and 4, 5-bis (diphenylphosphino) -9, 9-dimethylxanthene (151.428mg, 0.26mmol) in dioxane (50mL) was stirred at room temperature under nitrogen for 10 minutes. Then ethyl 1- (6-bromo-5-fluoropyridin-2-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylate (2g, 5.23mmol), Cs were added at room temperature₂CO₃(5.116g, 15.70mmol) and tert-butyl carbamate (0.736g, 6.28 mmol). The reaction mixture was then heated at 90 ℃ overnight and then cooled to room temperature. The reaction mixture was filtered through a pad of celite. The filtrate was concentrated under reduced pressure and then purified by flash column chromatography on silica gel (eluent: petroleum ether/EtOAc 100/0 to petroleum ether/EtOAc 80/20). The desired fractions were collected, and the solvent was concentrated to dryness under reduced pressure to give the desired product as a yellow solid (1800mg, yield: 82.2%).

1- (6-amino-5-fluoropyridin-2-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid ethyl ester, Compound 29f

1- (6- ((tert-butoxy)Carbonyl) amino) -5-fluoropyridin-2-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid ethyl ester (0.9g, 2.15mmol) and HCl/MeOH (18mL, 4M) were stirred at 30 ℃ for 1H. The mixture was concentrated to dryness. To the residue was added saturated K₂CO₃Aqueous solution (50 mL). The mixture was extracted with EtOAc (50 mL. times.3). The combined organic layers were passed over Na₂SO₄Drying, filtration and concentration of the filtrate to dryness gave the product as an orange gum (650mg, yield: 94.9%).

G.1- (8-Fluoroimidazo [1,2-a ]]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid ethyl ester, Compound (I) Substance 29g

In N₂Next, ethyl 1- (6-amino-5-fluoropyridin-2-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylate (650mg, 2.043mmol) was dissolved in EtOH (20 mL). To the suspension was added 2-bromo-1, 1-diethoxyethane (805.057mg, 4.085mmol), followed by HBr (2mL, 48% aq). The resulting mixture was then refluxed for 12 hours and cooled to room temperature. The solvent was removed under reduced pressure. The residue was purified by silica gel flash column chromatography (petroleum ether: ethyl acetate: 10:1 to 1: 1). The purified fractions were collected, and the solvent was concentrated under reduced pressure to give the product as a pale yellow solid (320mg, yield: 45.8%).¹H NMR(400MHz,CHLOROFORM-d)δppm 1.40(t,J＝7.2Hz,3H),4.42(q,J＝7.1Hz,2H),6.91(dd,J＝4.0,7.9Hz,1H),7.04(dd,J＝8.0,9.4Hz,1H),7.12(s,1H),7.70(s,1H),8.30(s,1H)。

H.1- (8-fluoroimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid, compounds 29h

I.N- (6-bromo-5-methylpyridin-3-yl) acetamide, Compound 29i

A solution of 5-amino-2-bromo-3-methylpyridine (1g, 5.35mmol) in acetic anhydride (8mL) was heated at 100 ℃ for 12 h. The solution was evaporated to dryness. The residue was dissolved in DCM. The organic layer was treated with 10% K₂CO₃Washing with water, separating, and removing with MgSO 2₄Drying, filtration and evaporation gave the crude product (1.26g, 100%). This compound was used in the next step without further purification.

⁶J.N- (6- ((dimethyl (oxo) -lambda-sulfinyl) amino) -5-methylpyridin-3-yl) acetamide, Compound 29j

A mixture of N- (6-bromo-5-methylpyridin-3-yl) acetamide (0.7g, 3.06mmol), S-dimethylsulfoximine (0.28g, 3.06mmol), Xantphos (0.19g, 0.33mmol) and cesium carbonate (2.98g, 9.17mmol) in F (5mL) was washed with N₂The stream was degassed for 30 minutes. Addition of Pd₂(dba)₃(0.14g, 0.15mmol), and the mixture was heated in a sealed tube at 100 ℃ overnight. Pouring the mixture into water and passingThe layers were filtered. The organic layer is substituted with CH₂Cl₂Extracting, separating, and purifying with MgSO 2₄Dry, filter and concentrate to dryness to give the crude product as a brown oil. The crude product was passed through preparative LC (stationary phase: conventional SiOH 15 μm 25g Interchim, mobile phase: 10Gradient from 0% DCM to 95/5 DCM/MeOH). The purified fractions were collected and the solvent was evaporated to dryness to give the product (0.56g, 76%). LC-MS (ES, M/z) [ M +1 ]]⁺242.3

⁶((5-amino-3-methylpyridin-2-yl) imino) dimethyl-lambda-thione, Compound 29k

Mixing N- (6- ((dimethyl (oxo) -lambda)⁶A mixture of-thioalkyl) amino) -5-methylpyridin-3-yl) acetamide (0.56g, 2.32mmol) and potassium hydroxide (0.45g, 6.96mmol) in EtOH (10mL) was refluxed for 6 hours. Pour solution into chilled water and use CH₂Cl₂The product is extracted. The organic layer is treated with K₂CO₃Washing with 10% aqueous solution, separating, and purifying with MgSO 4₄Dried and filtered. The solvent was evaporated to dryness to afford the title compound, which was used in the next step without purification.

⁶L.N- (6- ((dimethyl (oxo) -lambda-sulfinyl) amino) -5-methylpyridin-3-yl) -1- (8-fluoroimidazole And [1,2-a ]]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 29

1- (8-fluoroimidazo [1, 2-a)]A solution of pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid (0.1g, 0.32mmol), ((5-amino-3-methylpyridin-2-yl) imino) dimethyl-lambda 6-thione (0.06g, 0.32mmol), HATU (0.14g, 0.38mmol) and DIPEA (0.08mL, 0.48mmol) in DMF (6mL) was stirred at room temperature for 12H. The mixture was poured into ice water. EtOAc was added and the organic layer was separated with 10% K₂CO₃Washing with an aqueous solution over MgSO₄Dried and filtered. The solvent was evaporated to give the crude product as a brown oil. Passing the crude product through preparative LC(stationary phase: conventional SiOH 15 μm 25g Interchim, mobile phase: gradient of 100% DCM to 95/5 DCM/MeOH). The purified fractions were collected and the solvent was evaporated to dryness. The residue was dissolved in DIPE. The solid was filtered and dried to give the product (91mg, 57.7%).¹H NMR(400MHz,DMSO-d6)δppm 2.15(s,3H),3.37(s,6H),7.41-7.46(m,2H),7.47-7.49(m,1H),7.76(d,J＝2.21Hz,1H),7.77-7.78(m,1H),8.23(d,J＝2.21Hz,1H),10.38(s,1H)。LC-MS:(ES,m/z):[M+1]⁺496.2

Example 30

N- (6- ((dimethyl (oxo) -lambda)⁶-Thioalkylene) amino) -5- (trifluoromethyl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 30

N- (6-chloro-5- (trifluoromethyl) -3-pyridinyl) acetamide, Compound 30a

A solution of 6-chloro-5- (trifluoromethyl) pyridin-3-amine (0.35g, 1.78mmol) in acetic anhydride (6mL) was heated at 100 ℃ for 12 hours. The solution was evaporated to dryness. The residue was dissolved in DCM. The organic layer was treated with 10% K₂CO₃Washing with water, separating, and removing with MgSO 2₄Drying, filtration and evaporation gave the crude product (0.44g, 100%). This compound was used in the next step without further purification.

⁶N- (6- ((dimethyl (oxo) -lambda-sulfinyl) amino) -5- (trifluoromethyl) -3-pyridinyl) acetamide, compound 30b

A mixture of N- (6-chloro-5- (trifluoromethyl) -3-pyridinyl) acetamide (0.4g, 1.68mmol), S-dimethyl sulfoximine (0.156g, 1.68mmol), Xantphos (0.107g, 0.18mmol) and cesium carbonate (1.6g, 5.03mmol) in dioxane (6mL) was washed with N₂The stream was degassed for 30 minutes. Addition of Pd₂(dba)₃(0.08g, 0.08mmol) and the mixture was heated in a sealed tube at 100 ℃ overnight. Pouring the mixture into water and passingThe layers were filtered. The organic layer is substituted with CH₂Cl₂Extracting, separating, and purifying with MgSO 2₄Dry, filter and concentrate to dryness to give the crude product as a brown oil. The crude product was purified by preparative LC (stationary phase: conventional SiOH 15 μm 25g Interchim, mobile phase: 100% DCM to 95/5DCM/MeOH gradient). The purified fractions were collected and the solvent was evaporated to dryness to give the product (0.21g, 42%).¹H NMR(400MHz,DMSO-d6)δppm 2.04(s,3H),3.32(s,6H),8.19(d,J＝2.6Hz,1H),8.43(d,J＝2.5Hz,1H),10.07(s,1H)。

⁶((5-amino-3-methylpyridin-2-yl) imino) dimethyl-lambda-thione, Compound 30c

Mixing N- (6- ((dimethyl (oxo) -lambda)⁶A mixture of-thioalkyl) amino) -5- (trifluoromethyl) -3-pyridyl) acetamide (0.2g, 0.7mmol) and potassium hydroxide (0.14g, 2.1mmol) in EtOH (8mL) was heated at reflux for 6 h. Pour solution into chilled water and use CH₂Cl₂The product is extracted. The organic layer is treated with K₂CO₃Washing with 10% aqueous solution, separating, and purifying with MgSO 4₄Dried and filtered. The solvent was evaporated to dryness to give the crude product (0.18g, 100%).¹H NMR(400MHz,DMSO-d6)δppm 3.31(s,6H),5.00(s,2H),7.19(d,J＝2.8Hz,1H),7.76(d,J＝2.5Hz,1H)。

⁶D.N- (6- ((dimethyl (oxo) -lambda-sulfinyl) amino) -5- (trifluoromethyl) pyridin-3-yl) -1- (8- Fluoroimidazo [1,2-a ] s]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 30

1- (8-fluoroimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid (0.15g, 0.47mmol), ((5-amino-3-methylpyridin-2-yl) imino) dimethyl-Lambda⁶A solution of thione (0.12g, 0.47mmol), HATU (0.21g, 0.56mmol) and DIPEA (0.12mL, 0.71mmol) in DMF (5mL) was stirred at room temperature for 12 h. The mixture was poured into ice water. EtOAc was added and the organic layer was separated with 10% K₂CO₃Washing with an aqueous solution over MgSO₄Dried and filtered. The solvent was evaporated to give the crude product as a brown oil. The crude product was purified by preparative LC (stationary phase: conventional SiOH 15 μm 25g Interchim, mobile phase: 100% DCM to 95/5DCM/MeOH gradient). The purified fractions were collected and the solvent was evaporated to dryness. The residue (0.2g) was dissolved in DIPE. The solid was filtered and dried to give the product (150 mg). The product was dissolved in DCM. With 10% K₂CO₃The aqueous solution washes the solution. The organic layer was separated over MgSO₄Dry, filter, and evaporate the solvent to dryness. The residue was dissolved in DIPE. The solid was filtered and dried to give the desired compound (0.092g, 36%).¹H NMR(400MHz,DMSO-d₆)δppm 3.44(s,6H),7.42-7.54(m,3H),7.78(s,1H),8.30(d,J＝2.2Hz,1H),8.64(br s,2H),10.73(s,1H)。LC-MS:(ES,m/z):[M+1]⁺550.3

Example 31

1- (8-fluoroimidazo [1,2-a ] pyridin-5-yl) -N- (6- (S-methylsulfonylimino) -5- (trifluoromethyl) pyridin-3-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, compound 31

A.2-methanesulfonyl-5-nitro-3- (trifluoromethyl) pyridine, Compound 31a

A solution of 2-chloro-5-nitro-3- (trifluoromethyl) pyridine (1g, 4.41mmol) and sodium thiomethoxide (0.31g, 4.41mmol) in DMF (10mL) was stirred at room temperature for 12 h. The mixture was poured into water. The organic layer is substituted with CH₂Cl₂Extracting, separating, and purifying with MgSO 2₄Drying, filtration and concentration to dryness gave compound (1.1g, 100%). This compound was used in the next step without any further purification.

B.6-Methylsulfonyl-5- (trifluoromethyl) pyridin-3-amine, Compound 31b

A mixture of 2-methanesulfonyl-5-nitro-3- (trifluoromethyl) pyridine (0.5g, 2.1mmol) and Raney nickel (0.5g) in EtOH (15mL) was hydrogenated in a Parr reactor (3 atmospheres) at room temperature for 3 hours. The catalyst is added inFiltered off over a pad with CH₂Cl₂Washed and the filtrate was concentrated to dryness. The residue was purified by preparative LC (stationary phase: conventional SiOH 15 μm 25g Interchim, mobile phase: gradient from 100% DCM to 95/5 DCM/MeOH). The fractions were collected and the solvent was evaporated to dryness to give the compound (0.18, 41%). LC-MS (ES, M/z) [ M +1 ]]⁺209.2

C.1- (8-Fluoroimidazo [1, 2-a)]Pyridin-5-yl) -N- [ 6-methanesulfonyl-5- (trifluoromethyl) -3-pyridine Base of]Conversion of (E) -5- (trifluoromethyl) pyrazole-4-carboxamideCompound 31c

1- (8-fluoroimidazo [1, 2-a)]A solution of pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid (0.245g, 0.768mmol), 6-methylsulfanyl-5- (trifluoromethyl) pyridin-3-amine (0.16g, 0.768mmol), HATU (0.35g, 0.922mmol) and DIPEA (0.2mL, 1.15mmol) in DMF (8mL) was stirred at room temperature for 12H. The mixture was poured into ice water. EtOAc was added and the organic layer was separated with 10% K₂CO₃Washing with an aqueous solution over MgSO₄Dry, filter and evaporate the solvent to dryness. The residue was purified by preparative LC (stationary phase: conventional SiOH 15 μm 25g Interchim, mobile phase: gradient from 100% DCM to 95/5 DCM/MeOH). The fractions were collected and the solvent was evaporated to dryness to give the compound (0.27g, 70%).¹H NMR(500MHz,DMSO-d₆)δppm 2.61(s,3H),7.26-7.56(m,3H),7.78(s,1H),8.48(d,J＝1.6Hz,1H),8.66(s,1H),9.03(s,1H),10.98(s,1H)。LC-MS:(ES,m/z):[M+1]⁺505.5

1- (8-Fluoroimidazo [1, 2-a)]Pyridin-5-yl) -N- (6- (S-methylsulfonylimino) -5- (trifluoromethyl) Pyridin-3-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 31

1- (8-fluoroimidazo [1, 2-a)]Pyridin-5-yl) -N- [ 6-methylsulfanyl-5- (trifluoromethyl) -3-pyridinyl]A solution of-5- (trifluoromethyl) pyrazole-4-carboxamide (0.27g, 0.535mmol), iodobenzene diacetate (0.43g, 1.34mmol) and ammonium carbamate (0.167g, 2.14mmol) in MeOH (7mL) was stirred at room temperature for 12 h. The organic layer was extracted with AcOEt, separated and MgSO₄Dried, filtered and evaporated to dryness. The residue was purified by preparative LC (stationary phase: conventional SiOH 15 μm 25g Interchim, mobile phase: gradient from 100% DCM to 95/5 DCM/MeOH). Collecting fractionsAnd the solvent was evaporated to dryness. The residue (0.2g) was dissolved in DIPE. The solid was filtered and dried to give compound (0.1g, 35%).¹H NMR(400MHz,DMSO-d₆)δ4.57(s,1H),7.43-7.58(m,3H),7.79(s,1H),8.71(s,1H),8.76(s,1H),9.18(s,1H),11.38(s,1H)。LC-MS:(ES,m/z):[M+1]⁺536.5

Example 32

N- (6- ((dimethyl (oxo) -lambda)⁶-Thioalkylene) amino) -5-fluoropyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 32

N- (6-chloro-5-fluoro-3-pyridinyl) carbamic acid tert-butyl ester, compound 32a

A solution of 6-chloro-5-fluoropyridin-3-amine (0.8g, 5.46mmol) in acetic anhydride (7mL) was heated at 100 ℃ for 12 hours. The solution was evaporated to dryness. The residue was dissolved in DCM. The organic layer was treated with 10% K₂CO₃Washing with water, separating, and removing with MgSO 2₄Dried, filtered and evaporated in vacuo. The residue was purified by preparative LC (stationary phase: conventional SiOH 15 μm 25g Interchim, mobile phase: gradient from 100% DCM to 95/5 DCM/MeOH). The fractions were collected and the solvent was evaporated to dryness to give the product (0.44g, 43%).¹H NMR(500MHz,DMSO-d₆)δppm 2.10(s,3H),8.19(dd,J＝10.72,2.21Hz,1H),8.37(d,J＝2.21Hz,1H),10.51(br s,1H)

⁶N- (6- ((dimethyl (oxo) -lambda-sulfinyl) amino) -5-fluoro-3-pyridinyl) acetamide, compound 32b

A mixture of tert-butyl N- (6-chloro-5-fluoro-3-pyridinyl) carbamate (0.44g, 2.34mmol), S-dimethyl sulfoximine (0.22g, 2.34mmol), Xantphos (0.15g, 0.26mmol) and cesium carbonate (2.3g, 7.02mmol) in dioxane (5mL) was treated with N₂The stream was degassed for 30 minutes. Addition of Pd₂(dba)₃(0.11g, 0.12mmol), and the mixture was heated in a sealed tube at 100 ℃ overnight. Pouring the mixture into water and passingThe layers were filtered. The organic layer is substituted with CH₂Cl₂Extracting, separating, and purifying with MgSO 2₄Dry, filter and concentrate to dryness to give the crude product as a brown oil. The crude product was purified by preparative LC (stationary phase: conventional SiOH 15 μm 25g Interchim, mobile phase: 100% DCM to 95/5DCM/MeOH gradient). The purified fractions were collected and the solvent was evaporated to dryness to give the product (0.35g, 61%).¹H NMR(500MHz,DMSO-d₆)δppm 1.99-2.05(m,3H),3.24-3.30(m,6H),7.79(dd,J＝12.45,2.05Hz,1H),8.04(d,J＝1.89Hz,1H),9.98(s,1H)

⁶E.6- [ [ dimethyl (oxo) - λ -thioalkyl ] -A]Amino group]-5-fluoro-pyridin-3-amine, Compound 32c

Mixing N- (6- ((dimethyl (oxo) -lambda)⁶A mixture of-thioalkyl) amino) -5-fluoro-3-pyridyl) acetamide (0.35g, 1.43mmol) and potassium hydroxide (0.28g, 4.3mmol) in EtOH (10mL) was refluxed for 6 hours. Pour solution into chilled water and use CH₂Cl₂The product is extracted. The organic layer was treated with 10% K₂CO₃Washing with water, separating, and removing with MgSO 2₄Dried and filtered. The solvent was evaporated to dryness to give the crude product (0.2g, 69%). The compound was used directly in the next step without any further purificationAnd (5) carrying out the following steps.

1- (8-fluoroimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid (0.14g, 0.42mmol), 6- [ [ dimethyl (oxo) -lambda ] methyl [ (-)⁶-Thioalkylene radical]Amino group]A solution of-5-fluoro-pyridin-3-amine (0.09g, 0.42mmol), HATU (0.19g, 0.51mmol) and DIPEA (0.11mL, 0.63mmol) in DMF (6mL) was stirred at room temperature for 12 h. The mixture was poured into ice water. EtOAc was added and the organic layer was separated with 10% K₂CO₃Washing with an aqueous solution over MgSO₄Dried and filtered. The solvent was evaporated to give the crude product as a brown oil. The crude product was purified by preparative LC (stationary phase: conventional SiOH 15 μm 25g Interchim, mobile phase: 100% DCM to 95/5DCM/MeOH gradient). The purified fractions were collected and the solvent was evaporated to dryness. The residue was dissolved in DIPE. The solid was filtered and dried to give the product (58mg, 27%).¹H NMR(500MHz,DMSO-d₆)δppm 3.43(s,6H),7.41-7.50(m,3H),7.77(s,1H),7.89(dd,J＝11.98,1.89Hz,1H),8.23(d,J＝1.89Hz,1H),8.61(s,1H),10.65(s,1H)。LC-MS:(ES,m/z):[M+1]⁺500.2

Example 33

N- (5-chloro-6- ((dimethyl (oxo) -lambda)⁶-Thioalkylene) amino) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 33

N- (5, 6-dichloro-3-pyridinyl) acetamide, Compound 33a

A solution of 3-amino-5, 6-dichloropyridine (1g, 6.1mmol) in acetic anhydride (8mL) was heated at 100 ℃ for 12 hours. The solution was evaporated to dryness. The residue was dissolved in DCM. The organic layer was treated with 10% K₂CO₃Washing with water, separating, and removing with MgSO 2₄Dried, filtered and evaporated to give the crude product (1.3 g). This compound was used in the next step without further purification.

⁶N- [ 5-chloro-6- [ [ dimethyl (oxo) -lambda-sulfinyl ] alkyl]Amino group]-3-pyridyl]Acetamide, compound 33b

A mixture of N- (5, 6-dichloro-3-pyridinyl) acetamide (0.7g, 3.41mmol), S-dimethyl sulfoximine (0.32g, 3.4mmol), Xantphos (0.22g, 0.38mmol) and cesium carbonate (3.3g, 10.2mmol) in dioxane (10mL) was washed with N₂The stream was degassed for 30 minutes. Addition of Pd₂(dba)₃(0.08g, 0.08mmol) and the mixture was heated in a sealed tube at 100 ℃ overnight. Pouring the mixture into water and passingThe layers were filtered. The organic layer is substituted with CH₂Cl₂Extracting, separating, and purifying with MgSO 2₄Dry, filter and concentrate to dryness to give the crude product as a brown oil. The crude product was purified by preparative LC (stationary phase: conventional SiOH 15 μm 25g Interchim, mobile phase: 100% DCM to 95/5DCM/MeOH gradient). The purified fractions were collected and the solvent was evaporated to dryness to give the product (0.56g, 63%).¹H NMR(500MHz,DMSO-d₆)δ2.02(s,3H),3.38(s,6H),8.01(d,J＝2.52Hz,1H),8.16(d,J＝2.52Hz,1H),9.94(s,1H)。

⁶C.5-chloro-6- [ [ dimethyl (oxo) -lambda-thioalkyl ] -2]Amino group]Pyridin-3-amine, Compound 33c

Reacting N- [ 5-chloro-6- [ [ dimethyl (oxo) -lambda ]⁶-Thioalkylene radical]Amino group]-3-pyridyl]A mixture of acetamide (0.56g, 2.14mmol) and potassium hydroxide (0.423g, 6.4mmol) in EtOH (10mL) was heated at reflux for 6 h. Pour solution into chilled water and use CH₂Cl₂The product is extracted. The organic layer is treated with K₂CO₃Washing with 10% aqueous solution, separating, and purifying with MgSO 4₄Dried and filtered. The solvent was evaporated to dryness to give the crude product (0.44 g). This compound was used in the next step without further purification.

⁶D.N- (5-chloro-6- ((dimethyl (oxo) -lambda-sulfinyl) amino) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide, Compound 33

1- (8-fluoroimidazo [1, 2-a)]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxylic acid (0.12g, 0.37mmol), 5-chloro-6- [ [ dimethyl (oxo) - λ⁶-Thioalkylene radical]Amino group]A solution of pyridin-3-amine (0.083g, 0.37mmol), HATU (0.17g, 0.45mmol), and DIPEA (0.097mL, 0.56mmol) in DMF (6mL) was stirred at room temperature for 12 h. The mixture was poured into ice water. EtOAc was added and the organic layer was separated with 10% K₂CO₃Washing with an aqueous solution over MgSO₄Dried and filtered. The solvent was evaporated to give the crude product as a brown oil. The crude product was purified by preparative LC (stationary phase: conventional SiOH 15 μm 25g Interchim, mobile phase: 100% DCM to 95/5DCM/MeOH gradient). The purified fractions were collected and the solvent was evaporated to dryness. The residue was passed through a reversed phase (stationary phase): YMC-actus Triart C1810 μm 30 × 150mm, mobile phase: gradient 75% NH₄HCO₃0.2%, 25% ACN to 35% NH₄HCO₃0.2%, 65% ACN). The fractions were collected and the solvent was evaporated to dryness. The residue was dissolved in DIPE. The solid was filtered and dried to give compound (0.053g, 27%).¹H NMR(500MHz,DMSO-d₆)δ3.43(br s,6H),7.36-7.56(m,3H),7.77(br s,1H),8.13(br s,1H),8.35(br s,1H),8.61(br s,1H),10.61(br s,1H)。LC-MS:(ES,m/z):[M+1]⁺516.2

Biological examples

In vitro assays include assays to determine cell morphology, protein expression and/or cytotoxicity, enzyme inhibitory activity, and/or the subsequent functional consequences of treating cells with the compounds of the invention. Alternative or additional in vitro assays may be used to quantify the ability of an inhibitor to bind to a protein or nucleic acid molecule within a cell.

Inhibitor binding can be measured by radiolabelling the inhibitor prior to binding, isolating the inhibitor/target molecule complex and determining the amount of radiolabel binding. Alternatively or additionally, inhibitor binding can be determined by running competition experiments in which the new inhibitor is incubated with purified protein or nucleic acid that binds to a known radioligand. Detailed conditions for an exemplary system for determining compounds of formula (I) as inhibitors of MALT1 of the present invention are set forth in the biological examples below.

Such assays are exemplary and are not intended to limit the scope of the invention. The skilled practitioner will appreciate that conventional assay methods can be modified to develop equivalent or other assay methods that can be used to equally assess activity or otherwise characterize compounds and/or compositions as described herein.

In vitro testing

Biological example 1

MALT1 biochemical protease assay

Used as a substrateAnd full-length MALT1 protein (Strep-MALT1(1-824) -His) purified from baculovirus-infected insect cells, MALT1 protease activity was evaluated in an in vitro assay. The tetrapeptide LRSR is coupled to AMC (7-amino-4-methylcoumarin) and provides a quenched fluorogenic substrate for MALT1 protease (SM biochemical). Cleavage of AMC from an arginine residue resulted in an increase in coumarin fluorescence measured at 460nm (excitation 355 nm). The final assay buffer consisted of 10nM FL MALT1 protein, 200. mu.M Ac-LRSR-AMC, 50mM Tris pH 7.5, 0.6M citrate, 1mM DTT, 1mM EDTA, 0.05% BSA, and 1.5% DMSO. Test compounds were added to black 384-propiplate (Perkin Elmer) in an amount of 50nL per well of 100% DMSO. The test compound concentration was made to range from 30 μ M to 0.5nM using 11 dilution gradients (1: 3). Background signal was measured from control wells containing assay buffer without enzyme, which served as Low Controls (LC). High Control (HC) values were generated using reactions with enzymes but without compound treatment. The compounds were preincubated with MALT1 enzyme for 50 minutes at room temperature. The substrate was then added and the fluorescence was measured in Labsystems fluoroskan at excitation 355nm and emission 460nm to determine time 0. The reaction was then incubated at room temperature for 4 hours and fluorescence was measured. For IC₅₀Calculated, time point 0 was subtracted from the 4 hour time point to correct for any potential autofluorescence of the compound. The enzyme reaction was linear during the 4 hour incubation. Characterization of the substrate Ac-LRSR-AMC determined the Mie constant K at 200. mu.M_M。

Calculate IC using the formula₅₀Value (Zprime should be)>0.5)：

LC-median of low control values

Low control: enzyme-free reactions

HC is the median of the high control values

High control: reactions with enzymes

% effect 100- [ (sample-LC)/(HC-LC) × 100]

% control (sample/HC). times.100

% Controlmin ═ sample-LC)/(HC-LC) × 100

Fitting the best fit curve to% Controlmin by the least squares sum methodGraph with compound concentration. Thereby obtaining an IC₅₀Value (inhibitory concentration causing 50% inhibition). The slope of the curve estimated from the hill coefficient is also obtained.

IC₅₀And (3) calculating:

where y is the estimated response

UB is the upper limit

LB ═ lower limit

h is peak height

For "Lexis Dose Response Curve fixing" version 1.0. Table 2 shows the result data.

TABLE 2：

Biological example 2

PMA-induced IL2 product in Jurkat cells

Jurkat cells were cultured in complete RPMI1640 medium containing 10% fetal bovine serum, 10mM HEPES, 100 units/mL penicillin and 100. mu.g/mL streptomycin. Compounds were made in DMSO as 2-fold to 4-fold serial dilutions prior to assay. Volumes of 10 μ L DMSO dilution compound per well were further diluted into 240 μ L RPMI1640 complete medium. Jurkat cells were harvested by centrifugation at 1200RPM for 5 minutes, washed once with RPMI1640 medium, and cultured at 1.25X 10⁶cell/mL concentration cells were suspended in fresh complete RPMI1640 medium. Jurkat cells (2X 10) were grown in a volume of 160. mu.L⁵Individual cells) were seeded in each well of a 96-well plate. mu.L of the compound diluted in RMPI 1640 complete medium was added to each well at 37 ℃ with 5% CO₂Was incubated with Jurkat cells for 30 minutes. Add 20. mu.L volume of dilution to each wellPMA/ionomycin in RMPI 1640 complete Medium (81 nM/1.3uM, ebioscience, Cat. No. 00-4970-93, respectively). At 37 deg.C, 5% CO₂After incubation in the incubator for 20 hours, the supernatant was harvested. By ELISA (IL2 Duoset, R)&D Systems, catalog number DY202) to evaluate IL-2 concentration. The colorimetric intensity at 450nm was read by a Spectramax plate reader and analyzed using Softmax Pro software. Cell viability was assessed by the Cell Titer Glo kit (Promega, catalog No. G7571) using a Victor Luminescence reader (Victor 3V 4202938 manufactured by Perkin Elmer). Table 3 shows the resulting data.

Biological example 3

Human IL6/IL10 Mesoscale assay

NF_KB signaling regulates the secretion of a variety of cytokines, including IL6 and IL 10. The Mesoscale assay was used to measure cytokine IL6 and IL10 secretion from TMD8 ABC-DLBCL cells. NF by MALT1 or BTK inhibitor_KInhibition of B signaling results in decreased secretion of IL 6/10.

TMD8 cells were propagated in RPMI-1640(Sigma Aldrich) supplemented with 10% fetal bovine serum (HyClone), 1mM sodium pyruvate (Invitrogen), 2mM L-glutamine (Sigma Aldrich), and 1% PenStrep (Sigma Aldrich). The number of cell passages should not exceed 30. During the culture period, the cells should be maintained at a concentration of between 0.5 million cells/mL to 2.5 million cells/mL, and the cells should be supplemented with fresh 50 μ M β -mercaptoethanol every 2 to 3 days. Beta-mercaptoethanol was not used during the mesoscale assay.

For Mesoscale assay, 100,000 TMD8 cells were seeded into each well of a black 96-well plate with a clear bottom (Corning #3904) and test compounds were added in 9 dilution gradients (1:2) to concentrations ranging from 15 μ M to 58.6nM (final DMSO concentration 0.3%). DMSO control wells were used to determine the maximum signal (high control (HC)). Treatment with BTK inhibitor RN486 (9 dilutions of 1:2) at doses ranging from 30nM to 131pM served as a treatment for NF_KPositive control for B-pathway inhibition, and for determining maximum inhibition (low control: (LC)). The compounds and cells were incubated at 37 ℃ and 5% CO₂The cells were incubated for 24 hours (measurement volume 150. mu.L). After 24 hours of incubation, 50. mu.L of the supernatant was transferred to an MSD plate (V-Plex purification Panel 1 (human) kit, Mesoscale (MSD)) and incubated for 2 hours at room temperature with vigorous shaking (600 rpm). After incubation, plates were washed 3 times with PBS + 0.05% Tween-20 and 25. mu.L of detection antibody solution (IL 6 in dilution 3) was added to each well&IL10 antibody (MSD)), followed by incubation for 2 hours at room temperature with vigorous shaking (600 rpm). After 3 washes with PBS + 0.05% Tween-20, plates were incubated with 150 μ L of 2x reading buffer T and read on a SECTOR imager.

Calculate IC using the formula₅₀Value (Zprime should be)>0.5)：

LC (BTK inhibitor) ═ median of low control values

Low control: reaction at 100nM final concentration

HC is the median of the high control values

High control: reaction with DMSO, no compound (final DMSO 0.3%)

% effect 100- (sample-LC)/(HC-LC) × 100

% control (sample/HC). times.100

% Controlmin ═ sample-LC)/(HC-LC) × 100

The best fit curve was fitted to the plot of% control versus compound concentration by the least squares sum method. Thereby obtaining an IC₅₀Value (inhibitory concentration causing 50% signal reduction). The slope of the curve estimated from the hill coefficient is also obtained.

Calculate IC using the formula₅₀Value (Zprime should be)>0.5)：

LC (ATP-GLO) ═ median of low control values

Low control: cell-free reaction, medium only

HC (ATP-GLO) — median of high control values

High control: reaction with DMSO in the Presence of cells but without Compounds

% effect 100- (sample-LC)/(HC-LC) × 100

% control (sample/HC). times.100

% Controlmin ═ sample-LC)/(HC-LC) × 100

The best fit curve was fitted to the plot of% control versus compound concentration by the least squares sum method. Thereby obtaining an IC₅₀Values (inhibitory concentration causing 50% cytotoxicity). The slope of the curve estimated from the hill coefficient is also obtained. Table 3 shows the resulting data.

TABLE 3：

Biological example 4

Proliferation assay

To assess anti-proliferative effects, MALT1 inhibitor test compounds can be tested in a 4-day proliferation assay using three different DLBCL cell lines. Can be evaluated in classical NF_KTwo ABC-DLBCL cell lines with activating mutations in the B pathway (OCI-Ly3(CARD11 mutation, MYD88 mutation, and a20 mutation), TMD8(CD79B mutation and MYD88 mutation), which are typically directed against NF_KB-pathway inhibition is sensitive. GCB-DLBCL cell line (OCI-Ly7) (which did not show active NF_KB signaling) can serve as a negative control to exclude compounds with general cytotoxic effects.

OCI-Ly3 cells were propagated in RPMI-1640(Sigma Aldrich) supplemented with 10% fetal bovine serum (HyClone), 2mM L-glutamine (Sigma Aldrich), and 1% PenStrep (Sigma Aldrich). TMD8 cells were propagated in RPMI-1640(Sigma Aldrich) supplemented with 10% fetal bovine serum (HyClone), 1mM sodium pyruvate (Invitrogen), 2mM L-glutamine (Sigma Aldrich), and 1% PenStrep (Sigma Aldrich). During the culture period, the cells should be maintained at a concentration of between 0.5 million cells/mL to 2.5 million cells/mL, and the cells should be supplemented with fresh 50 μ M β -mercaptoethanol every 2 to 3 days. Beta-mercaptoethanol was used during the proliferation assay. OCI-Ly7 cells were propagated in IMDM (ThermoFisher) supplemented with 10% fetal bovine serum (HyClone), 2mM L-glutamine (Sigma Aldrich), and 50. mu.g/mL gentamicin. The number of cell passages should not exceed 30.

To assess antiproliferative effects, 400nL of test compound can be spotted in each well of a 96-well plate (Costar, catalog No. 3904). 10,000 TMD8, 10,000 OCI-Ly3, or 2,000 OCI-Ly7 cells were seeded into 100. mu.L of medium per well and incubated at 37 ℃ and 5% CO₂The following incubations were carried out for 4 days. The number of cell spreads can be selected based on the growth curve to ensure linear cell growth. After 4 days of incubation, 50 μ L of CellTiterGLO reagent (Promega) can be added to each well and after 10 minutes of incubation at room temperature, luminescence can be measured on Envision.

IC can be calculated using the following equation₅₀Value (Zprime should be)>0.5)：

LC-median of low control values

Low control: cell-free response

HC is the median of the high control values

High control: reaction in the presence of cells but without compounds

% effect 100- (sample-LC)/(HC-LC) × 100

% control (sample/HC). times.100

% Controlmin ═ sample-LC)/(HC-LC) × 100

The best fit curve can be fitted to the plot of% control versus compound concentration by the least squares sum method. IC50 values (inhibitory concentration causing 50% cytotoxicity) were thus obtained. The slope of the curve estimated from the hill coefficient may also be obtained.

Biological example 5

Study of tumor efficacy

Can be 5% CO in air at 37 deg.C₂OCI-Ly3(DSMZ, Cat. ACC 761) human diffuse large B-cell lymphoma tumor cells were cultured in vitro in RPMI medium supplemented with heat-inactivated fetal bovine serum (10% v/v) and 2mM L-glutamine 200 mM. The cells may be subjected to routine subculture once a week. Cells grown in exponential growth phase can be harvested and subjected toCounting, and placing the cell suspension in Matrigel^TM(Corning Matrigel^TMLow growth factor basement membrane) at a 1:1 ratio for tumor cell seeding.

OCI-Ly3 cells (1:1 medium (Matrigel) could be cultured by the inguinal region of each animal^TMVolume of 200. mu.L) of 10X 10⁶Individual cells) was subcutaneously inoculated into male NSG (nod. cg-Prkdc)^scid Il2rg^tm1WjlSzJ) mice. The date of tumor cell inoculation can be expressed as day 0. Tumor measurements can be monitored twice weekly starting on day 7 post-implantation until the mean tumor volume is 169 ± 42mm³At this point, mice can be randomized into treatment groups by tumor volume. The compound or vehicle can be administered orally once or twice daily, depending on body weight (5mL/kg), until the termination of the study. Tumor measurements and body weights can be recorded twice weekly.

The endpoints of the study were tumor growth inhibition, maximum tumor burden (individual tumor size equals 10% of body weight) and weight loss greater than 20% of body weight at the start of treatment. The percent weight change can be calculated using the following formula: weight change [ (C-I)/I ═]100, wherein C is the current body weight and I is the body weight at the beginning of the treatment. Tumor size can be measured twice per week in two dimensions using calipers, and can be measured in mm using the following formula³Volume is expressed in units: v is 0.5a × b²Wherein a and b are the long and short diameters of the tumor, respectively. Complete tumor regression (CR) was defined as a decrease below the palpation limit (20 mm)³) The tumor of (2). Partial tumor regression (PR) is defined as a tumor that is reduced at least half the original tumor volume. The shortest duration of CR or PR in three or more consecutive tumor measurements is required to consider CP or PR as persistent.

Summary statistics (including mean and Standard Error of Mean (SEM)) are provided for tumor volumes in each group at each time point, and the differences in tumor volumes are shown in the corresponding study tables. Statistical analysis of tumor volume differences between groups can be assessed using a two-way ANOVA repeat measurement test followed by Tukey post hoc testing using GraphPad Prism version 6.

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the generic variations, modifications and/or adaptations coming within the scope of the following claims and their equivalents.

Claims

1. A compound of formula (I)

Wherein

R₁Is independently selected from pyrazolo [1,5-a]Pyridyl and imidazo [1,2-a]Heteroaryl of pyridyl; wherein R is₁Optionally substituted independently with one or two substituents selected from methyl, ethyl, fluoro, chloro, cyano or aminocarbonyl;

G₁is N or C (R)₄)；

R₄independently selected from triazolyl, 1- (methoxy) ethyl, oxazolyl, isoxazolyl, pyrazolyl, pyrrolyl, thiazolyl, tetrazolyl, oxadiazolyl and imidazolyl; wherein R is other than 1-methoxyethyl₄Optionally independently selected from oxo, C_1-4Alkyl, carboxyl, methoxycarbonyl, aminocarbonyl, hydroxymethyl, aminomethyl, (dimethylamino) methyl, amino, methoxymethyl, trifluoromethyl, amino (C)_2-4Alkyl) amino or cyano substituted with one or two substituents; or R₄Independently selected from tetrahydrofuran-2-yl,CH₃SO₂-、(CH₃)₂S (= O) (= N) -and CH₃(NH=)(O=)S-；

R₇is hydrogen, methyl, ethyl or fluorine;

2. The compound of claim 1, wherein R₁Independently selected from pyrazolo [1,5-a]Pyridin-4-yl and imidazo [1,2-a]Pyridin-5-yl; wherein R is₁Optionally substituted independently with a substituent selected from chloro, aminocarbonyl and cyano.

3. The compound of claim 1, wherein R₁Independently selected from (7-aminocarbonyl) pyrazolo [1,5-a]Pyridin-4-yl, (7-chloro) pyrazolo [1,5-a]Pyridin-4-yl, (7-cyano) pyrazolo [1,5-a]Pyridin-4-yl, (8-aminocarbonyl) imidazo [1,2-a]Pyridin-5-yl, (8-chloro) imidazo [1,2-a]Pyridin-5-yl, (8-cyano) imidazo [1,2-a]Pyridin-5-yl and (8-fluoro) imidazo [1,2-a]Pyridin-5-yl.

4. The compound of claim 1, wherein R₂Is trifluoromethyl or methylsulfonyl.

5. The compound of claim 1, wherein R₃Independently selected from trifluoromethyl, cyano and chloro.

6. The compound of claim 4, wherein R₃Is trifluoromethyl.

7. Root of herbaceous plantThe compound of claim 1, wherein G₂Is N.

8. The compound of claim 1, wherein R₄Independently selected from 2H-1,2, 3-triazol-2-yl, oxazol-2-yl, 4-methyloxazol-2-yl, 5-methyloxazol-2-yl, 1H-pyrazol-1-yl and tetrahydrofuran-2-yl.

9. The compound of claim 1, wherein R₄Independently selected from 1 (A), (B), (C), (^*R) -methoxyethyl, 1: (^*S) -methoxyethyl group, ((S) -methoxyethyl group)^*R) -tetrahydrofuran-2-yl and (^*S) -tetrahydrofuran-2-yl.

10. The compound of claim 1, wherein R₅Hydrogen or chlorine or trifluoromethyl.

11. The compound of claim 1, wherein

R₂is trifluoromethyl or methylsulfonyl;

G₁is N or C (R)₄)；

R₃is trifluoromethyl;

R₄independently selected from triazolyl, oxazol-2-yl, 4-methyloxazol-2-yl, 5-methyloxazol-2-yl, 1H-pyrazol-1-yl, 1- (methoxy) ethyl, tetrahydrofuran-2-yl, CH₃SO₂-、(CH₃)₂S (= O) (= N) -and CH₃(NH=)(O=)S-；

R₅Independently selected from hydrogen, methyl, ethyl, fluorine, chlorine, bromine, methoxy, triFluoromethyl and cyano groups;

R₆is hydrogen, methyl or trifluoromethyl;

R₇is hydrogen, methyl, ethyl or fluorine;

12. A compound of formula (I)

Wherein

R₂is trifluoromethyl or methylsulfonyl;

G₁is N or C (R)₄)；

R₃is trifluoromethyl;

R₄independently selected from triazol-2-yl, pyrazol-1-yl, oxazol-2-yl, 4-methyloxazol-2-yl, 5-methyloxazol-2-yl, 1- (m-ethyl-1-methyl-2-yl)^*R) -methoxyethyl, 1: (^*S) -methoxyethyl group, ((S) -methoxyethyl group)^*R) -tetrahydrofuran-2-yl group, ((R) -tetrahydrofuran-2-yl group^*S) -tetrahydrofuran-2-yl, CH₃SO₂-、(CH₃)₂S (= O) (= N) -and CH₃(NH=)(O=)S-；

R₆is hydrogen;

R₇is hydrogen;

13. The compound of claim 1, independently selected from the group consisting of:

5- (4- ((5-chloro-6- (2))H-1,2, 3-triazol-2-yl) pyridin-3-yl) carbamoyl) -5- (trifluoromethyl) -1H-pyrazol-1-yl) imidazo [1,2-a]Pyridine-8-carboxamide;

N- (5-chloro-6- (2)H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (8-cyanoimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

N- (5-chloro-6- (1H-pyrazol-1-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1, 2-)a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

N- (6- (2H-1,2, 3-triazol-2-yl) -5- (trifluoromethyl) pyridin-3-yl) -1- (8-fluoroimidazo [1, 2-)a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

1- (8-fluoroimidazo [1, 2-)a]Pyridine-5-yl) -N- (6- (methylsulfonyl) -5- (trifluoromethyl) pyridin-3-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

N- (5-chloro-6- (oxazol-2-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1, 2-)a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

N- (5-chloro-6- (2)H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (8-methylimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

N- (5-chloro-6- (2)H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (methylsulfonyl) -1H-pyrazole-4-carboxamide;

N- (5-chloro-6- (5-methyloxazol-2-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1, 2-)a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-formamide;

N- (5-chloro-6- (4-methyloxazol-2-yl) pyridin-3-yl) -1- (8-fluoroimidazo [1, 2-)a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

1- (7-cyanopyrazolo [1, 5-)a]Pyridin-4-yl) -5- (trifluoromethyl) -substituted benzeneN- (2- (trifluoromethyl) pyridin-4-yl) -1H-pyrazole-4-carboxamide;

4- (5- (trifluoromethyl) -4- ((2- (trifluoromethyl) pyridin-4-yl) carbamoyl) -1H-pyrazol-1-yl) pyrazolo [1,5-a]Pyridine-7-carboxamide;

N- (5-chloro-6- (2)H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (7-cyanopyrazolo [1,5-a]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

1- (7-chloropyrazolo [1, 5-)a]Pyridin-4-yl) -5- (trifluoromethyl) -substituted benzeneN- (2- (trifluoromethyl) pyridin-4-yl) -1H-pyrazole-4-carboxamide;

N- (5-chloro-6- (2)H-1,2, 3-triazol-2-yl) pyridin-3-yl) -1- (7-chloropyrazolo [1,5-a]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamides

4- (4- ((5-chloro-6- (2))H-1,2, 3-triazol-2-yl) pyridin-3-yl) carbamoyl) -5- (trifluoromethyl) -1H-pyrazol-1-yl) pyrazolo [1,5-a]Pyridine-7-carboxamide;

(^*S)-N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (8-fluoroimidazo [1, 2-)a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*R)-N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (8-chloroimidazo [1, 2-)a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*R)-N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (8-fluoroimidazo [1, 2-)a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*S)-N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (8-chloroimidazo [1, 2-)a]Pyridin-5-yl) -5- (trifluoromethyl))-1H-pyrazole-4-carboxamide;

(^*S)-N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (7-chloropyrazolo [1, 5-)a]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*R)-N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (7-chloropyrazolo [1, 5-)a]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*S)-N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (7-cyanopyrazolo [1, 5-)a]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*R)-N- (5-chloro-6- (tetrahydrofuran-2-yl) pyridin-3-yl) -1- (7-cyanopyrazolo [1, 5-)a]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*S)-N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (7-cyanopyrazolo [1, 5-)a]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(*R)-N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (7-cyanopyrazolo [1, 5-)a]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*S)-N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (7-chloropyrazolo [1, 5-)a]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

(^*R)-N- (5-chloro-6- (1-methoxyethyl) pyridin-3-yl) -1- (7-chloropyrazolo [1, 5-)a]Pyridin-4-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

N- (6- ((dimethyl (oxo) -lambda)⁶Thioalkylene) amino) -5-methylpyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

N- (6- ((dimethyl (oxo) -lambda)⁶Thioalkylene) amino) -5- (trifluoromethyl) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamides；

1- (8-fluoroimidazo [1, 2-)a]Pyridine-5-yl) -N- (6- (S-methylsulfonylimino) -5- (trifluoromethyl) pyridin-3-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

N- (6- ((dimethyl (oxo) -lambda)⁶Thioalkylene) amino) -5-fluoropyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamide;

and

N- (5-chloro-6- ((dimethyl (oxo) -lambda)⁶Thioalkylene) amino) pyridin-3-yl) -1- (8-fluoroimidazo [1,2-a]Pyridin-5-yl) -5- (trifluoromethyl) -1H-pyrazole-4-carboxamides

Or a pharmaceutically acceptable salt form thereof.

14. A pharmaceutical composition comprising a compound according to claims 1 to 13 and at least one of a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient and a pharmaceutically acceptable diluent.

15. The pharmaceutical composition of claim 14, wherein the composition is a solid oral dosage form.

16. The pharmaceutical composition of claim 14, wherein the composition is a syrup, an elixir or a suspension.

17. A method of treating a disease, syndrome, condition or disorder wherein said disease, syndrome, condition or disorder is affected by inhibition of said MALT1, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.

18. The method of claim 14, wherein the disease, syndrome, condition or disorder is selected from diffuse large B-cell lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), and mucosa-associated lymphoid tissue (MALT) lymphoma, Rheumatoid Arthritis (RA), psoriatic arthritis (PsA), psoriasis (Pso), Ulcerative Colitis (UC), crohn's disease, Systemic Lupus Erythematosus (SLE), asthma, and Chronic Obstructive Pulmonary Disease (COPD).

19. A method of treating a disease, syndrome, condition or disorder selected from diffuse large B-cell lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), and mucosa-associated lymphoid tissue (MALT) lymphoma, Rheumatoid Arthritis (RA), psoriatic arthritis (PsA), psoriasis (Pso), Ulcerative Colitis (UC), crohn's disease, Systemic Lupus Erythematosus (SLE), asthma, and Chronic Obstructive Pulmonary Disease (COPD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.

20. Use of a compound according to claim 1 for the manufacture of a medicament for the treatment of a disease, syndrome, disorder or condition selected from diffuse large B-cell lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), and mucosa-associated lymphoid tissue (MALT) lymphoma, Rheumatoid Arthritis (RA), psoriatic arthritis (PsA), psoriasis (Pso), Ulcerative Colitis (UC), crohn's disease, Systemic Lupus Erythematosus (SLE), asthma, and Chronic Obstructive Pulmonary Disease (COPD) in a subject in need thereof.

21. Use of a compound according to claim 1 in a method for treating a disorder selected from diffuse large B-cell lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), and mucosa-associated lymphoid tissue (MALT) lymphoma, Rheumatoid Arthritis (RA), psoriatic arthritis (PsA), psoriasis (Pso), Ulcerative Colitis (UC), crohn's disease, Systemic Lupus Erythematosus (SLE), asthma, and Chronic Obstructive Pulmonary Disease (COPD) in a subject in need thereof.

22. A method of treating a disease, syndrome, condition, or disorder, wherein the disease, syndrome, condition, or disorder is affected by inhibition of MALT1, the method comprising administering to a subject in need thereof a therapeutically effective amount of (a) a MALT1 inhibitor, and (B) an agent selected from the group consisting of BTK inhibitors, SYK inhibitors, PKC inhibitors, PI3K pathway inhibitors, BCL family inhibitors, JAK inhibitors, PIM kinase inhibitors, B-cell antigen binding antibodies, immune cell redirecting agents, immune modulating agents, anti-PD 1 antibodies, and anti-PD-L1 antibodies;

wherein the MALT1 inhibitor is a compound of formula (I)

Wherein

G₁is N or C (R)₄)；

R₄independently selected from triazolyl, 1- (methoxy) ethyl, oxazolyl, isoxazolyl, pyrazolyl, pyrrolyl, thiazolyl, tetrazolyl, oxadiazolyl and imidazolyl; wherein R is other than 1-methoxyethyl₄Optionally independently selected from oxo, C_1-4Alkyl, carboxyl, methoxycarbonyl, ammoniaAlkylcarbonyl, hydroxymethyl, aminomethyl, (dimethylamino) methyl, amino, methoxymethyl, trifluoromethyl, amino (C)_2-4Alkyl) amino or cyano substituted with one or two substituents;

R₇is hydrogen, methyl, ethyl or fluorine;

23. The method of claim 19, wherein the BTK inhibitor is ibrutinib.

24. The method of claim 19, wherein the B cell antigen binding antibody is rituximab.

25. The method of claim 19, wherein the immunomodulatory agent is daratumab.